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ABSTRACT 
 
 
THE PHYSICS OF MEMBRANE EMULSIFICATION AND APPLICATIONS FOR 
CONTROLLED DRUG DELIVERY 
 
Robert F. Meyer 
 
John C. Crocker 
 
In many applications employing particles, the distribution of particle sizes has 
significant influence over the properties of the resultant material, and this holds 
especially true for many pharmaceutical products.  In the case of depot formulations 
made of drug-loaded polymer microspheres, particle size significantly impacts the rate 
and duration of drug release.  Thus, if particle size can be controlled, formulation 
characteristics can be engineered to better meet the needs of the specific situation.  Cross-
flow membrane emulsification (XME) is a method for manufacturing uniformly sized 
emulsion droplets which can be used for many applications, including production of 
drug-loaded polymer microspheres.  In XME, a dispersed phase is forced through an 
orifice in a planar membrane into a simple shear flow set up by a second continuous 
phase flowing parallel to the membrane surface, thereby generating an emulsion.  Though 
XME has become a popular technique for researchers generating monodisperse 
emulsions, there has been insufficient characterization of the physics of the XME 
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process.  This is true for both simple binary fluid systems, as well as the more complex 
fluid systems used for the generation of drug-loaded microspheres.  In this work, we 
describe a unique XME system that allows for visualization of the process, providing 
access to details likely unseen by previous researchers.  First employing our system for 
the study of pure fluids, we successfully show that a simple force balance can be used to 
model the size of emulsion droplets as a function of process conditions.  We also show 
that the range of applicability of our model corresponds to the region of simple fluid 
dripping, and that the XME process undergoes a dripping-jetting transition much like the 
common household faucet.  Extending the methods to a more complex case when 
dissolved polymers, drugs and surfactants are present, we find generally that our earlier 
results hold true, but only if dynamic interfacial tension is taken into account.  Ultimately 
we show that drug-loaded polymer microspheres of uniform size can be reliably and 
predictably manufactured across a range of process conditions, and thus we conclude that 
XME has the potential to produce advanced controlled release formulations. 
 viii
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Chapter 1: Introduction 
1.1 Research Motivation 
For many chronic conditions, the success a drug has in managing a disease is 
directly related to how well the drug concentration is maintained within the therapeutic 
window that maximizes efficacy and minimizes side effects.  Traditional drug therapy 
usually consists of an oral dosage form that is administered once daily.  Although this has 
been standard for many years, this route of administration can lead to variability due to 
many factors, including poor patient compliance to the recommended dosing schedule, 
and interaction of the drug or formulation with food and drink.  Furthermore, this 
administration route suffers from the drawbacks that many drugs are degraded or poorly 
absorbed in the gut, and first-pass metabolism can significantly reduce the amount of 
drug that reaches circulation.  Oral administration also results in a drug being dosed to the 
entire body, rather than being delivered to only the desired location.  Because these 
mechanisms increase the total amount of drug that must be administered to reach the 
target concentration in the blood, and because different patients absorb and metabolize 
drugs differently, significant variability can be seen between patients taking oral 
medication.  Ultimately, deviation of drug concentration outside of the therapeutic 
window can lead to a higher incidence of side effects or relapse, and in some instances, it 
can lead to patient hospitalization. 
Parenteral drug formulations circumvent many problems associated with oral 
administration, and thus have inherent advantages over traditional therapy.  Although 
they are more expensive to manufacture and generally must be administered by a medical 
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professional, parenterals have benefits such as lower dose, local delivery, and reduced 
variability between patients.  Long acting release (LAR) parenteral formulations in 
particular have been shown to improve patient compliance, reduce drug variability and 
side effects, improve clinical outcomes, and decrease hospitalizations and the cost of 
care1-4.  For these reasons, advancing the science geared towards development of such 
treatment forms is a valuable research goal. 
1.2 Background 
There are many approaches for developing LAR parenteral formulations, and 
embedding drug in a matrix of polymer is certainly one of the more popular strategies.  In 
a classical method used to manufacture drug-loaded microparticles, an organic solvent is 
mixed with drug and a biodegradable polymer to form the dispersed phase, while water 
and surfactant form the continuous phase.   The dispersed phase is emulsified in the 
continuous phase, and then the organic solvent is extracted and evaporated, resulting in 
solid drug-loaded polymer microspheres.  After washing and drying, the microspheres 
form a drug product suitable for parenteral administration.  Microspheres such as these 
have been developed as several drug products used to provide release periods ranging 
from 1 week to 6 months. 
There have been at least 10 commercial products of this type developed for the 
U.S. market over the last 20 years5.  Although these LAR products all improve upon 
formulations that are administered daily, no formulation has achieved the gold standard 
of a constant drug release rate over an extended period.  Instead, current LAR 
formulations reduce the daily rise and fall of drug levels in the body, and instead provide 
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drug levels that rise and fall a few times a month.  As an example of this, we examine 
clinical data from a study that compared an oral and LAR formulation of naltrexone, an 
opioid receptor antagonist used for treatment of alcohol dependence.    
 
Figure 1.1 – Pharmacokinetic profiles of immediate release (IR) 
and long acting release (LAR) formulations of naltrexone. 
Figure 1.1 displays our graphical representation of pharmacokinetic data extracted 
from a clinical study comparing an immediate release (IR) 50 mg once-daily oral dose of 
naltrexone to a LAR 380 mg once-monthly intramuscular microsphere injection3.  For 
drugs such as naltrexone, the optimal formulation would rapidly raise the level of drug in 
the patient's blood stream to the desired concentration, and would then maintain that 
same concentration, releasing additional drug at the same rate that the body eliminates it 
from circulation.  The LAR formulation clearly eliminates the daily rise and fall of drug 
levels in the blood when compared to the IR formulation, but it is far from the ideal 
formulation, which would maintain concentrations at near constant levels.  Instead, it 
exhibits a tri-phasic release profile, with peaks on days 0, 3 and ~15.  Although this is not 
of significance for this drug, in many cases the spike seen in the LAR formulation can 
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cause increased side effects or disease flare-up6.  Thus, microsphere formulations that can 
better control rate and extent of drug release will in many cases result in improved patient 
care and better clinical outcomes. 
Because drug is released from microspheres by both diffusion through and 
degradation of the polymer matrix, stringent control over particle size is a convenient 
method for manipulating release rate.  This general concept has been demonstrated by 
several researchers who used high shear emulsification to produce microspheres with 
wide particle size distributions, then sieved the product into several size fractions, each 
with its own unique release profile7-9.  The transport of drug through the microspheres 
was modeled as a function of particle diameter, while also taking polymer degradation 
rate into account.  Finally, Berchane et al.9 showed that by mixing microspheres with 
different sizes and polymer molecular weights, they could achieve a pre-specified release 
profile. 
1.3 Research Aims 
Because most emulsification techniques used for generating polymer 
microspheres result in polydisperse particle size distributions, a technique that allows for 
accurate and precise particle size control would be a significant improvement in the state 
of the art.  In this thesis, we aim to develop a robust and scalable manufacturing method 
for continuously producing sterile monodisperse polymer microspheres.  We aim to 
develop a theoretical understanding of how process conditions affect particle size, by first 
studying the emulsification of pure, simple fluids.  Then we aim to expand this 
understanding to non-ideal fluid systems used for generating drug-loaded polymer 
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microspheres.  We aim to use this understanding to demonstrate our manufacturing 
method's utility for producing large quantities of drug loaded polymer microspheres.  
Finally, we aim to lay the groundwork for developing an ideal microsphere formulation 
exhibiting the desired rate and extent of release, including development of a system for 
testing this drug release in vitro.  
1.4 Thesis Outline 
This thesis is organized as follows.  In Chapter 2, we first review polymer-based 
controlled release dosage forms in general.  Then we look at the methodology for 
generating polymer microsphere formulations using emulsification followed by solvent 
extraction and evaporation.  With that as a backdrop, we review the state of the art for 
producing monodisperse emulsions, including the methods of manufacture and 
mathematical descriptions of the processes.  We focus this review specifically on the 
technique known as cross-flow membrane emulsification.  Then we examine research 
where monodisperse emulsions were produced from systems containing polymers and 
surfactants.  Finally, we review in greater detail instances where control over particle size 
was used as a method to manipulate drug release from polymer microsphere 
formulations. 
In Chapter 3, we describe the materials and methods used in this research.  
Specifically, we describe the apparatus that we developed for manufacturing 
monodisperse emulsions.  We also describe the equipment and methods for examining 
the emulsion production process.  We explain our techniques for measuring physical 
properties relevant to emulsions, and some results from those measurements.  And we 
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give details on efforts to characterize our emulsification system, through both basic 
mathematical as well as more advanced numerical modeling.  Finally, we provide 
additional details on the materials used to generate polymer microparticles, the model 
drug we load into the particles, and our method for measuring drug release from the 
particles. 
In Chapter 4 we describe the production of monodisperse emulsions of simple 
fluids using cross-flow membrane emulsification. This work, titled "Universal Dripping 
and Jetting in a Transverse Shear Flow",  has been previously published in Physical 
Review Letters in May 2009.10     A model for predicting the size of droplets as a function 
of system geometry, process flow rates and physical properties is presented.  We also 
describe where the system transitions from dripping to jetting, and draw comparisons to 
the well-studied case of the dripping faucet.   
Chapter 5 describes our efforts to expand cross-flow membrane emulsification 
from simple, pure fluid systems to more complicated systems containing dissolved 
polymers and surfactants.  This work, titled, "Producing Monodisperse Drug-Loaded 
Polymer Microspheres via Cross-Flow Membrane Emulsification: The Effects of 
Polymers and Surfactants", was previously published in Langmuir in September 2010.11  
We show that emulsions generated from both simple and complex fluids can be produced 
across a range of sizes and rates, and the models that describe the size of the resultant 
droplets work reasonably well for both systems.  We show that dynamic interfacial 
tension affects the size of droplets, especially at low production rates, but that fluid 
viscosity and elasticity behave ideally under the conditions studied.  Finally, we show 
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that cross-flow membrane emulsification can be used to generate highly uniform solid 
drug-loaded polymer microspheres. 
Chapter 6 contains a description of future work that could be performed to 
translate the demonstrated manufacturing methods into a commercializable formulation 
of a model drug, haloperidol.  Literature is reviewed that describes LAR formulations of 
haloperidol, including a manuscript that we contributed to, "A rapid method for creating 
drug implants: Translating laboratory-based methods into a scalable manufacturing 
process", published in the Journal of Biomedical Materials Research Part B: Applied 
Biomaterials in May 2010.12  Specifically, we lay out the calculations for what a 30 day 
LAR formulation of haloperidol would look like, and describe the emulsification and in 
vitro release experiments to be performed in order to achieve the goal of generating an 
ideal drug release profile. 
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Chapter 2: Literature Review 
2.1 Marketed long acting release medications and their 
formulations 
Development of long acting release (LAR) formulations of drug encapsulated in a 
matrix of polymer is a commercially viable formulation strategy, and several products of 
this type are approved for marketing in the United States.  Gliadel Wafers® (polifeprosan 
20 with carmustine implant) are used to treat individuals with high-grade malignant 
blastoma.  The biodegradable discs are implanted directly into the brain during 
craniotomy, and have been shown to extend patient lives by delivering an extended dose 
of drug higher than what is tolerable when the drug is delivered systemically1.  Zoladex® 
(goserelin acetate implant) is used for treating patients with advanced cancers of the 
prostate.  The 1 mm diameter biodegradable rod is implanted subcutaneously and releases 
a synthetic hormone for a 1 or 3 month period.  Lupron Depot®, Vivitrol®, and Risperdal 
Consta® are all biodegradable microsphere based formulations.  Lupron Depot® 
(leuprolide acetate for depot suspension), available in 1 to 4 month formulations, is 
indicated for men with prostate cancer, similar to Zoladex®, and is also indicated for 
women with endometriosis or fibroids, and children with central precocious puberty.  
Vivitrol® (naltrexone for extended-release injectable suspension) is indicated for 
treatment of alcohol dependence, and is delivered as an intramuscular injection that is 
dosed every 4 weeks.  Risperdal Consta® (risperidone) long acting injection, indicated for 
the treatment of bipolar I disorder as well as schizophrenia, is administered every 2 
weeks as a deep intramuscular injection2.  Finally, NuvaRing® (etonogestrel /ethinyl 
estradiol vaginal ring) is a non-biodegradable contraceptive ring which releases two 
 10
hormones over a three week period, and is a popular alternative to daily contraceptive 
pills.  All of these products have been shown clinically to improve patient outcomes 
relative to short acting daily doses of the same or similar medicines. 
The LAR formulations currently available on the U.S. market come in a variety of 
shapes and sizes, and those specific products just described are formed into the shapes of 
rings, discs, rods and microspheres.  The polymers used to formulate LAR products are 
just as varied.  The non-biodegradable copolymer as ethylene-vinyl acetate (EVA) has 
been used successfully, and there are several biodegradable polymers in use either in 
research or on the market, such as polycaprolactone (PCL), poly(lactic acid) (PLA), 
poly(glycolic acid) (PGA), and copolymers such as  poly[bis(p-carboxyphenoxy) 
propane-co-sebacic acid] (polifeprosan) and poly(DL-lactide-co-glycolide) (PLG)3.  The 
biodegradable polymers are all polyesters, and degrade through hydrolytic cleavage of 
the ester bond, thus releasing the payload of drug.   
Of the many polymers and geometries that could be studied for generating LAR 
formulations, we choose to focus on PLG based microspheres.  The PLG copolymer 
certainly has been studied the most, and has enjoyed commercial success in a number of 
products, including Zoladex® rods, and Lupron Depot®, Vivitrol®, and Risperdal Consta® 
microspheres.  A wide variety of types of PLG are available off the shelf.  Specifically, 
the following traits can be altered so as to tune polymer hydrophilicity, crystallinity, 
degradation rate, and ultimately drug release rate.  These traits are adjustable by varying 
the lactide to glycolide ratio (100:0 to 50:50), the polymer molecular weight (10 kDa to 
140 kDa), and the polymer end group (acid or ester terminus).  Microspheres are studied 
frequently as well, and methods for their manufacture are numerous.  The particles can be 
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delivered via injection with a small needle, and including those listed above, at least 10 
products have been commercialized for the U.S. market3. 
2.2 Methods of manufacture for long acting release 
formulations 
The most basic method for encapsulating drugs within PLG microspheres is 
known in the literature as the oil-in-water (o/w) emulsion solvent extraction method3.  
This method is depicted graphically in Figure 2.1.  In the method, the continuous phase 
(CP) is prepared through mixing water with a surfactant, typically poly(vinyl alcohol).  
The dispersed phase is prepared by mixing the drug and polymer together with an organic 
solvent, typically dichloromethane.  The dispersed phase is then emulsified within the 
continuous phase using any number of methods.  The organic solvent is chosen such that 
it is sparingly soluble in water, and can thus be extracted slowly over time.  As the 
solvent is extracted, the emulsion droplets shrink and solidify, ultimately yielding solid 
drug-loaded polymer microspheres.   As a final step, the microspheres are washed to 
remove any residual surfactant, and either filtered and air dried, or lyophilized while 
contained within a suspending medium.  
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Figure 2.1 – Oil-in-water emulsion / solvent extraction method for 
producing drug-loaded polymer microspheres. 
In order to generate drug-loaded polymer microspheres using the method 
described above, we need only pick the formulation and the emulsification method.  The 
other steps can follow the common recipes available in the literature.  Focusing first on 
the emulsification method, we seek a technique that is robust, scalable, continuous, and 
can generate sterile monodisperse particles over a wide size range.  
2.3 Methods of manufacture for uniformly sized emulsions 
There are many ways to make particles, and the general technique is to start with 
something big and make it small through application of force.  When generating 
dispersions, high-shear emulsification and spraying processes are two common high-
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throughput techniques that result in wide particle size distributions.  The key to making 
uniform particles is to control the balance of forces between what holds particles 
together, and what tears them apart.  For liquids, interfacial tension is the key force 
holding the liquid together, while a variety of forces can be used to tear a liquid apart.  
Here we will briefly review some of the major methodologies. 
Dripping of a liquid by gravity from a household faucet is the most common 
example of how uniform droplets can be generated through the application of a force, and 
perhaps because of its common occurrence, the system has been studied in great detail.  
Harkins and Brown wrote a classic paper in 1919 that described the size of droplets 
produced from a dripping needle tip in relation to the diameter of the needle, the fluid 
density and the strength of the interfacial tension force4.  The analysis is not as 
straightforward as one might initially assume, because the size of the drop that falls is 
always smaller than a simple force balance would predict.  They then turned the analysis 
around, and proposed measuring the weight of a falling drop as a means of determining 
the interfacial tension of a fluid.  This method remains popular today, but a sound 
theoretical analysis of the system was not developed until recently.  In 1993, Eggers 
wrote a paper that described the nature of the hydrodynamic singularity which occurs 
when a droplet detaches from a needle tip.5  Then in 1994, Eggers and Dupont wrote a 
paper describing a one-dimensional "slender jet" approximation to the Navier-Stokes 
equation that could be applied to the case of the dripping faucet6.  This development was 
important, because it enabled the use of computers to numerically simulate the dripping 
faucet geometry in a time-efficient manner.  Finally, in 2005 Yildirim et al. published a 
paper called "Analysis of the Drop Weight Method", which utilized the equations of 
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Eggers and Dupont to perform a vast number of numerical simulations7.  They were able 
to numerically simulate the original results of Harkins and Brown, and also rephrase as a 
dimensionless correlation the dimensionless drop size as a function of the ratio of 
gravitational and interfacial tension forces, ultimately showing that by understanding the 
balance of forces, we can predict the size of particles being made. 
Gravity is a good force to use for generating droplets because it is widely 
available, but other forces such as electrostatic repulsion, mechanical motion, and fluid 
drag have the benefit of being adjustable, and thus the applied force can be tuned to break 
off a droplet of exactly the desired size.  Electro-hydrodynamic atomization (EHDA) is 
an interesting application of this idea.  In EHDA, a liquid is pumped through a needle tip,  
and an electric potential is applied between the needle and a counter-electrode.  When the 
electrostatic force exceeds the surface tension force, a thin column of liquid jets from the 
needle tip, and the column subsequently breaks up into monodisperse drops8-9.  The 
technique suffers from the drawback of painstakingly low flow rates (on the order of 100 
µL/hr), a problem that can be addressed through multiplexing.10  Using this method, 
droplets in the size range of hundreds of nanometers up to around 10 µm have been made 
for purposes that include drug delivery11-13. 
A particularly exciting example of monodisperse droplet generation using 
mechanical vibration was described by Berkland et al.14  In their method, a column of 
liquid flows through a needle or other orifice so that the liquid jets.  Using a piezoelectric 
transducer, a mechanical vibration is applied to the needle that precisely matches the 
most unstable wavelength predicted by Rayleigh's classic linear stability analysis15.   This 
mechanical forcing causes the liquid column to break up into a uniform stream of 
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droplets, and droplet sizes in the range of 25 to 500 µm have been generated.  The 
method has been used to generate drug-loaded PLG microspheres,16-17 and by mixing 
different monodisperse lots, they produced formulations that exhibit a constant release 
rate.   Unfortunately, the method has been patented, and little work has been performed 
outside of the originating laboratory.  Still, their pioneering work was early proof of the 
concept of engineered release profiles, and we seek to improve upon the efficiency and 
scalability of their technique. 
Another example of monodisperse droplet generation through application of a 
controlled force was presented by Umbanhowar, Prasad and Weitz.18  In that work, 
monodisperse droplets were produced by immersing a bent needle into a fluid vessel 
undergoing solid body rotation,  thus generating a co-flowing liquid stream at the needle 
tip.  The size of the droplets is determined by the balance of drag and interfacial forces, 
and a model to predict droplet diameter based on this force balance was presented.  
Droplet diameters between 2 and 200 µm were generated.  Subsequent studies in the 
same laboratory resulted in a related technique, where a circular needle was centered 
within an outer square tube, and monodisperse emulsions were generated.19  An even 
more unique geometry was presented by this laboratory, where a third collection tube was 
centered downstream from the circular injection needle and the square outer tube.  Using 
this geometry, they were able to generate monodisperse double emulsions, including 
core-shell microcapsules with tunable wall thickness.20   This technique, commonly 
called flow focusing, has enjoyed significant popularity and has been the subject of 
numerous investigations. 
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2.4 Review of cross-flow membrane emulsification 
Instead of making particles by applying drag from a co-flowing liquid stream, a 
cross-flowing liquid stream can be used.  When instead of a capillary, a microporous 
membrane is used, the technique is called cross-flow membrane emulsification (XME).  
When comparing all of the techniques for generating monodisperse particles, we find that 
XME meets our criteria, in that it is robust, scalable, continuous, and can generate sterile 
monodisperse particles over a wide size range.  A diagram depicting the XME process is 
displayed in Figure 2.2.   
 
Figure 2.2 – Diagram of cross-flow membrane emulsification 
(XME). 
In XME, the DP is forced by pressure through a membrane containing one or 
multiple small pores.  Meanwhile, the CP flows tangentially over the membrane surface.  
Because the phases are immiscible, when the DP contacts the CP, a droplet grows at the 
membrane surface.  As the droplet grows, the drag from the CP increases, until such point 
that the drag force exceeds the interfacial tension force.  The droplet then detaches from 
the membrane surface, and the process repeats.  When the flow rates from the two phases 
are constant, the process reaches a steady state, and the droplet grows to a repeatable size 
over and over again, yielding a monodisperse emulsion.  And by adjusting either the drag 
force or the interfacial tension force, different sizes of droplets can be produced.  
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Experiments described in later chapters show that droplet size is either independent or 
only a weak function of DP flow rate, a result that improves process robustness.  If 
components are fabricated from materials such as stainless steel and fluoroelastomer, 
then they can be sterilized through autoclaving, and thus are suitable for sterile 
processing.  Finally, the process is scalable, because membranes with multiple pores can 
be used such that the desired mass throughput is obtained.  Thus, the method meets the 
requirements we set for selection. 
Cross-flow membrane emulsification belongs to a more general class of 
membrane emulsification methods, and these methods are reviewed at the start of 
Chapters 4 and 5.  Looking just at XME, researchers have used numerous techniques to 
generate the cross-flow shown in Figure 2.2, and a variety of methods have been used to 
manufacture the microporous membrane.  Kosvintsev et al. adapted a cone and plate 
rheometer, well known to produce constant shear across the surface of the plate21.  In that 
study, they used commercially available silicon nitride membranes etched onto a silicon 
substrate, which exhibit a beautiful uniform array of straight-through microchannels.  
Surprisingly, their study resulted in fairly polydisperse particles.  Furthermore, they 
concluded that particles produced using the cone and plate geometry were no more 
uniform than those produced using a standard paddle stirrer.  The same research group 
later went on to produce drug-loaded microparticles using this method, but drug release 
profiles were not significantly more uniform than those based on conventional 
emulsification techniques22-23. 
Kobayashi et al. were one of the first research groups to use photolithography to 
generate silicon microporous membranes, and then use those membrane to generate 
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emulsions using XME.24-25  They were unique in that they generated both circular as well 
as oblong pores, and they concluded that oblong pores result in a more uniform size 
distribution, though this result has not been widely repeated by others, and circular pores 
are still the most common.   
Although not purely XME due to the presence of centrifugal forces, an interesting 
example of membrane emulsification using a rotating laser drilled stainless steel 
membrane was demonstrated by Vladisavljevic and Williams.26  Their study operated in 
batch mode, with the membrane tube spinning within an outer stationary fluid vessel, 
though a continuous set up was also described.  They showed that the low shear rates 
throughout their setup made possible the generation of large, shear labile droplets.  
Ultimately, their method produced droplets from 80 to 260 µm with uniformity of 5 to 
20%. 
Perhaps the most popular XME technique involves the use of Shirasu Porous 
Glass (SPG) as the membrane.  In this method, a DP is pumped through a (typically) 
cylindrical annulus made of microporous glass and into a cross-flowing CP.27  This 
method has also been successfully used for generating drug-loaded polymer 
microparticles, and one group of researchers generated PLA microparticles using both the 
XME SPG technique, as well as via conventional high shear emulsification.28-29  They 
found that both particle size uniformity as well as drug encapsulation efficiency were 
better for the XME technique.  Unfortunately, SPG membranes are fragile, and are not 
amenable to sterile processing, and thus are unsuitable for commercial applications. 
Looking now at the physics of XME, because of the well defined geometry and 
fluid properties, the basic system is amenable to both classical force balance descriptions, 
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as well as numerical simulations.  Abrahamse et al. published the earliest known 
computational fluid dynamics (CFD) simulation of the XME process, and we later 
followed their approach for our own modeling.30  CFD is particularly useful for gaining 
insight into the details of the XME process, and Abrahamse et al. published results 
showing how the pressure drop over and velocity within the pore is time-dependent, and 
also how the CP penetrates into the pore near the point of droplet snap off.    
A number of researchers have tried to apply force and/or torque balances to 
predict droplet size during XME.  Peng and Williams were one of the first to apply theory 
to their experimental results.31  They used a single 46 µm glass capillary embedded in 
epoxy and mounted within a 10 mm x 40 mm stainless steel flow channel.  Their 
theoretical method took into account drag, interfacial, buoyant and inertial forces, and 
though their graphical representation displayed good agreement between experiment and 
theory, they presented only 5 experimental data points of droplet size vs. CP flow 
velocity, with too little supporting information to draw an independent conclusion. 
An excellent application of the force balance approach to modeling of droplet size 
as a function of process conditions was performed by Husny and Cooper-White.32  Their 
work focused on modeling of droplet formation in T-shaped microchannels, which are a 
microfluidic analog to XME.  Unlike traditional XME, in the T-shaped microchannel 
geometry the "pore" spans the entire width of the CP channel, and thus the resultant 
droplets also span nearly the width of the channel.  Despite these complications, they 
presented a sophisticated force balance, as well as copious data to support their 
predictions.  Furthermore, the DP in their fluid system contained a dissolved polymer, 
poly(ethylene oxide), and they showed the effect of changes of polymer molecular weight 
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and viscosity ratio, and how under certain conditions satellite droplets resulting from the 
long fluid neck were produced along with the primary droplets. 
2.5 Application of controlled emulsification for engineered drug 
release 
Numerous examples have been presented demonstrating how drug-loaded 
microparticles can be generated from controlled emulsification techniques.  We also refer 
the reader to three recent review papers that discuss emulsification techniques including 
those described above, as well as other information of relevance to those seeking to 
produce polymer based drug-loaded microparticles.3, 33-34 
  Taking the design to the next level, and using monodisperse particles to engineer 
formulations with the desired release rate is a problem that has been studied by far fewer 
researchers.  Two research groups have made substantial contributions, and both groups 
solved the time-dependent diffusion equation with molecular weight dependent 
diffusivity.35-37 
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In the equation, c is the drug concentration, r is the radial position within the 
microsphere, D is the drug diffusivity within the polymer matrix, Mw is polymer 
molecular weight, and t is time.  The relationship of Mw with time is typically reported to 
be log linear, ln(Mw) = mt + b, and that again is the case here.  The Pack Laboratory at the 
University of Illinois went further, and measured the initial distribution of drug in the 
microspheres using confocal fluorescence microscopy, and then used those data as the 
model initial condition.  Both research groups were able validate their models for the 
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release of drug from monodisperse microspheres, and they also used polymer molecular 
weight and microsphere size as design parameters for engineering the desired release 
profile.   
This concludes what is only a brief review of the hundreds of papers that we have 
looked to for ideas and inspiration during the generation of this research.  Thus as we 
begin the chapters devoted to our own research, we end with a quotation often wrongly 
attributed to Isaac Newton, but still very appropriate for any researcher: "Bernard of 
Chartres used to compare us to dwarfs perched on the shoulders of giants.  He pointed out 
that we see more and farther than our predecessors, not because we have keener vision or 
greater height, but because we are lifted up and borne aloft on their gigantic stature."38  
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Chapter 3: Materials, Methods, and Preliminary Results 
3.1 Cross-Flow Membrane Emulsification 
Membrane emulsification describes a wide variety of techniques whereby a 
dispersed phase (DP) is forced through an orifice in a membrane into an immiscible 
continuous phase (CP), thereby generating an emulsion.  A subset of this wide field is 
cross-flow membrane emulsification (XME), where nascent drops are formed at the 
membrane pore while subjected to a transverse shear flow.  This process is represented 
below in Figure 3.1.  The drag force exerted by the CP increases as the drop grows larger, 
until such point that the interfacial tension force can no longer hold onto the drop, after 
which the drop detaches and the process begins anew.  It is this balance of drag and 
interfacial tension forces which allows for precise control over the size of the droplets 
which are produced via XME. 
 
 
Figure 3.1 – Schematic of the XME process and important 
parameters. 
This chapter is organized as follows.  First we describe the method and apparatus 
for generating emulsions via XME, followed by the visual and data recording systems.  
Next we describe the preparation of simple and complex fluid pairs, and the measurement 
of relevant physical and particle properties.  We describe the mathematics particular to 
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the fluid flow in our XME apparatus, and numerical simulations of those flows.  Next, 
downstream processing techniques for generating solid microspheres from emulsions 
made via XME are described.  Finally, we describe a model drug and an inline system for 
testing drug release from solid microspheres.  Where appropriate, we have included 
preliminary results from the described techniques so as to validate the results and 
illustrate their utility. 
3.1.1 Membrane Emulsifier 
A system for producing emulsions via cross-flow membrane emulsification is 
shown in Figure 3.2 and Figure 3.3.  Both CP and DP are pumped into their respective 
inlets from the bottom of the membrane holder.  After changing direction, the CP flows 
along the membrane surface down a long rectangular channel 6.4 mm wide by 3.2 mm 
high.  In some experiments, a solid insert is placed in the channel to decrease the height 
to 1.0 mm.  In the center of the channel, DP passes through the membrane and into the 
cross-flowing CP, generating a droplet.  The emulsion then travels down the remainder of 
the channel, and exits the membrane holder at the bottom, and finally proceeds to the 
collection vessel. 
 
Figure 3.2 – Solid representation of membrane emulsifier flow 
channels, membrane and optical path. 
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The membrane holder is machined from two highly polished 4 in. square blocks 
of aluminum alloy 6061, between which the membrane is sandwiched.  Two concentric 
rings contain double-seal Viton o-rings, thus sequestering the DP from the CP, and the 
CP from the ambient environment.  The membrane holder top and bottom are connected 
via four ¼"-20 stainless steel screws.  The 2 in. diameter membrane rests on the inner o-
ring during assembly, and is machined such that the o-ring is compressed appropriately 
and there is no lip between the membrane and the membrane holder.  The two 0.063 in. 
radius indentations in the membrane holder top are machined to hold two 1/8 in. right 
angle prisms mounted flush with the fluid channel wall, and a solvent proof optical epoxy 
holds the prisms in place.  A 1 in. diameter sapphire window rests on top of the channel 
and prisms, and this assembly allows the emulsification process to be viewed from both 
the top and the side. 
 
Figure 3.3 – Bottom view of membrane holder top (left), and top 
view of membrane holder bottom (right). 
Disk-shaped membranes are constructed of stainless steel and cut to 50 mm in 
diameter from 0.30 mm thick sheet stock.  For each membrane, a single pore is cut into 
the center of the membrane using one of three methods: laser drilling (Oxford Lasers, 
Shirley, MA), mechanical drilling (Roland Research Devices, Trenton, NJ), or electrical 
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discharge machining (EDM) (Makino / Hummingbird Precision Machine Co., Lacey, 
WA).  The pore dimensions for the various membranes are shown in Table 3.1, as 
measured via image analysis by fitting an ellipse to the pore perimeter.  Electron 
micrographs showing the different membrane pores are provided in Figure 3.4 and Figure 
3.5.   
Table 3.1 – Summary of pore dimensions of membranes used for XME. 
No. Side 
Method of 
Manufacture 
Major 
Dia. (µm) 
Minor 
Dia. (µm) 
Average 
Dia. (µm) 
Area 
(µm2) 
Perimeter 
(µm) 
1 Front Laser drilled 17 17 17 226 53
1 Back Laser drilled 12 11 11 101 36
2 Back Laser drilled 20 20 20 308 62
3 Front Mech. drilled 94 93 94 6904 295
3 Back Mech. drilled 174 171 173 23425 543
4 Front EDM 24 24 24 451 75
5 Front EDM 43 43 43 1464 136
6 Front EDM 64 64 64 3213 201
7 Front EDM 79 79 79 4868 247
8 Front EDM 101 100 101 7959 316
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(a) Membrane 1 front side 
 
 (b) Membrane 1 back side 
 
 
 
 
(c) Membrane 3 front side  (d) Membrane 3 back side 
Figure 3.4 – SEM images of laser and mechanically drilled 
membranes. 
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(a) Membrane 4 front side  (b) Membrane 5 front side 
 
 
 
(c) Membrane 6 front side  (d) Membrane 7 front side 
 
 
(e) Membrane 8 front side  
*All images courtesy of Leon Farber, 
Merck Center for Materials Science and 
Engineering 
Figure 3.5 – SEM images of electrical discharge machined 
membranes. 
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Figure 3.6 shows a process flow diagram containing the membrane emulsifier.  
The dispersed phase (DP) fluid is added to a 20 mL or 50 mL stainless steel syringe.  The 
syringe plunger is driven by a KDS100 syringe pump (KD Scientific, Boston, MA) with a 
maximum linear driving force of 88 N.  The desired flow rate is manually entered on the 
pump's digital display.  The fluid is pumped through 1/8 in. outer diameter Teflon tubing 
until it couples to a tee at the entrance to the membrane emulsifier.  A pressure transducer 
(SPT4V, Invensys, Milpitas, CA) is used to measure the DP static pressure at the same 
location. 
The continuous phase (CP) is added to a 4 L stainless steel pressure vessel.  The 
vessel is driven by a pressurized air source which is regulated between 0 and 100 psig.  
Upon applying pressure to the vessel, CP fluid is forced through a ball valve, woven filter 
and needle valve, all constructed of stainless steel.  The ball valve is used to shut off the 
flow absolutely, while the needle valve is used in combination with the pressure regulator 
to set the desired flow rate.  An inline flowmeter (FMTE4, DEA Engineering, Anza, CA) 
senses the flow rate, and this reading is recorded at a frequency of 1 Hz by the data 
acquisition system (OMB DAQ 56, Omega Engineering, Stamford, CT).  The CP travels 
through ¼" outer diameter stainless steel tubing until it reaches a tee where the static 
pressure is measured as the fluid enters the membrane emulsifier. 
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Figure 3.6 – Process flow diagram for XME. 
3.1.2 Microscope and optics 
A diagram of the microscope system used during membrane emulsification 
experiments is shown in Figure 3.7.  A standard C-mount 640 x 480 resolution 8-bit 
COHU 4915 CCD camera is used to collect video images at a rate of 30 interlaced frames 
per second.  The camera is mounted on an XYZ linear translation stage, providing two 
inches of travel in each direction.  Light is focused on the camera's detector by a set of 
one inch diameter achromat lenses.  The upper lens with a focal length of 150mm is fixed 
in place at the end of a six inch lens tube.  The lower lens is interchangeable, and lens 
with focal lengths of 35 mm, 50 mm, 75 mm, 150 mm, or 300 mm were used throughout 
the study, thus providing magnification levels of 4.3x, 3x, 2x, 1x, or 0.5x.   
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Figure 3.7 – Diagram of microscope system used during membrane 
emulsification experiments. 
3.1.3 Computer and Data Acquisition System 
Analog video from the COHU camera is digitized through a USB video link 
connector.  Video images are collected using Video Toolbox (version 1.65, Zarbeco, 
Randolph, NJ), processed using VirtualDub (version 1.6.19, virtualdub.org), and 
analyzed using ImageJ (version 1.38x, rsb.info.nih.gov) and Matlab (R2007a, The 
Mathworks, Natick, MA).  The Video Toolbox software timestamps each image with the 
date and time, using the system clock as the time source.  Video exists as a sequence of 
uncompressed TIFF gray-scale images.  All files are recorded to the system hard drive 
with the file name "date_fluid-system_magnification_file-number.avi".    
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The image length scale for each lens set is calibrated by imaging a standard 
micrometer slide or standard ruler in several different orientations and locations.  Using 
ImageJ, a line is placed on the image of the slide perpendicular to the hash marks, then a 
line intensity profile is generated, thus generating a graph with peaks corresponding to 
the center of each hash mark.  The average distance in pixels is then compared to the 
actual distance in microns, and thus the calibration ratio is determined.   
Table 3.2 – Scale calibration factors for lenses used to view XME. 
Mag. 
Focal 
Length 
(mm) 
Line 
Length 
(µm) 
Line 
Length 
(pixels)
Scale 
Ratio 
(µm/pixel)
FOV 
x 
(mm) 
FOV 
y 
(mm) 
0.5 300 1000 87 11.494 7.4 5.4 
1 150 3000 439 6.834 4.4 3.2 
2 75 1000 275 3.636 2.3 1.7 
3 50 1000 407 2.457 1.6 1.1 
*FOV = Field Of View 
 
The OMB-DAQ 56 data acquisition system collects data from various sensors, 
then digitizes and imports the data into Microsoft Excel.  The program is set up to collect 
one datum point each second from the CP and DP pressure transducers, the CP flow 
meter, and the ambient and process temperature sensors.  Calibration parameters are 
shown in Table 3.3. 
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Table 3.3 – Sensor calibration values. 
System / Parameter Value Units 
DP Pressure   
Scale 7.5 psig/V 
Offset -7.5 psig 
CP Flow  
Scale 1.173 mL/min/Hz 
Resolution 5 ms 
Edge rising  
CP Pressure   
Scale 1.673 psig/V 
Offset -1.673 psig 
3.2 Continuous Phase and Dispersed Phase Fluid Preparation 
3.2.1 Simple Systems 
In some work, simple binary systems are used for the CP and DP.  Typically, 
deionized (DI) water is used as the CP (18 MΩ/cm, Easypure Barnstead), and a variety of 
fluids are used for the DP.  Some examples are n-butanol, n-pentanol, n-hexanol, n-
decanol, dichloromethane, ethyl acetate, and their mixtures.  All chemicals are obtained 
through Fisher Scientific (Fairlawn, NJ) or Sigma (St. Louis, MO).  Each phase is 
saturated with the opposite phase and allowed to equilibrate overnight, so as to minimize 
mass transfer during emulsification. 
3.2.2 Complex Systems 
When generating drug-loaded polymer microspheres, the DP consists of the 
solvent dichloromethane (DCM), the biodegradable polymer poly(D,L-lactide-co-
glycolide) (PLG), and haloperidol as a model drug.  DCM was obtained from Fisher 
Scientific (Fairlawn, NJ).  PLG (50:50 D,L-lactide/glycolide, ester terminated, inherent 
viscosity = 0.82 dL/g in HFIP) was obtained from Birmingham Polymers (Pelham, AL). 
Haloperidol was obtained from Sigma (St. Louis, MO).  The CP consists of the surfactant 
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poly(vinyl alcohol) (PVA) dissolved in DI water.  PVA (22 kDa, 88% hydrolyzed) was 
obtained from Acros Organics (New Jersey, USA).   
For the production of polymer microspheres, CP is prepared by dissolving PVA in 
warm DI water at a concentration of 1% by weight.  After dissolution of the PVA, the 
solution is filtered through a 14 μm cellulose acetate filter and allowed to cool to room 
temperature.  DP is prepared by mixing haloperidol, PLG, and DCM in a closed container 
overnight. In most experiments, the DP contains 9% PLG and 1% haloperidol on a 
weight basis.  In some experiments, the concentrations are raised to 11% PLG and 1.2% 
haloperidol, in order to raise the DP viscosity and increase resistance to droplet rupture. 
3.3 Physical Property Measurements 
3.3.1 Viscosity 
Capillary viscometry is used exclusively for measurement of fluid shear viscosity.  
Viscometers with two different capillary diameters are used, type 0C and type 2 (Cannon 
Instrument Co., State College, PA).  The viscosity is measured by drawing the fluid 
through the narrow capillary, then measuring the time required to pass between two 
timing lines.  The viscosity µ is calculated as µ = kρt, where k is provided by the 
viscometer manufacturer, and ρ is the mass density.  In this case, k = 0.002665 mm2/s2 or 
0.09849 mm2/s2  for the type 0C and type 2 viscometers, respectively.  The ambient 
temperature is recorded but not actively controlled.  Typically, experiments are run in 
triplicate, and the average value is reported. 
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Figure 3.8 – Ubbelohde viscometer. 
3.3.2 Density 
The mass density of different fluids is measured by weighing the quantity of fluid 
required to fill a 50 mL volumetric flask to its fill line.  The mass density ρ is calculated 
as ρ = m/V, where m and V are the mass and volume, respectively.  Experiments are 
typically run in duplicate, and the average value is reported. 
3.3.3 Interfacial Tension 
The interfacial tension between the CP and DP fluid phases is measured using two 
different methods, namely, pendant drop profile analysis (PDPA) and the drop weight 
method.  Each method, however, uses the same instrument set up, which is shown in 
Figure 3.9. 
 
1/2X Mag. Adjustable stage CCD Camera 
Stainless steel needle Quartz cuvette
From Syringe pump 
Diffuser & Light source 
 
Figure 3.9 – Instrument set up used for interfacial tension 
measurements. 
 36
3.3.4 Pendant Drop Profile Analysis 
Before beginning, the phases are equilibrated in contact with each other.  As 
shown in Figure 3.9, a syringe pump is used to drip the DP into the CP at a controlled 
rate, generally from a needle tip.  However, droplets can also be formed through a 
membrane pore, and the analysis works equally well.  Videos of the dripping are 
recorded.  Image processing starts from high contrast images of attached droplets, 
thresholding and converting the image from 8-bit to binary, then finding the edge 
coordinates as well as the drop apex in the image matrix.  A coordinate transformation is 
then made to convert the drop apex to the zero position, and a scaling factor is added to 
give the coordinates proper SI units.  Figure 3.10 shows this graphically.   
 
 
Figure 3.10 – Coordinate system for pendant drop profile analysis. 
The edge coordinate array is then fit to the axisymmetric Laplace equation expressed in 
cylindrical coordinates1,  
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with the dimensionless variables defined as  
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and the boundary conditions 
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The Laplace equation expressed above has only two unknowns, γ and ΔpH = pHB – 
pHA, once the densities of each phase and the drop contour r = c(z) are known.  Using  a 
non-linear least squares optimization routine, we solve for γ and ΔpH, then use these 
values to calculate G.  This procedure is performed for each half of the drop, and the 
average of the two values is reported along with the sum of the squared errors.  An 
example starting image and resultant drop are shown in Figure 3.11 and Figure 3.12. 
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Figure 3.11 – Drop of 1-pentanol in water attached to 90 µm pore. 
 
Figure 3.12 – Laplace equation fit (solid line) to 1-pentanol image 
edge coordinates (diamonds).  The calculated interfacial tension γ = 
4.7 mN/m is similar to the literature result2 of γ = 4.4 mN/m ± 0.2 
mN/m.  Also shown are the differential pressure inside and outside the 
drop at the apex, p, the sum of squared errors, SSE, the shape 
parameter, G, the drop volume, V, and the drop surface area, S.   
 
 39
Using the edge coordinate array, the volume of the drop, V, is calculated using the 
formula for a solid of revolution 
 ( )[ ]∫= H dzzcV 0 2π  (3.9) 
and the surface area, S, is calculated similarly using 
 ( ) dz
dz
dczcS
H
2
0
12 ⎟⎠
⎞⎜⎝
⎛
+= ∫π . (3.10) 
Because movies are shot instead of individual images, it is possible to determine 
the reproducibility of interfacial tension measurements over time using an individual drop 
or multiple drops.  Similarly, when surfactants are present in the system, the drop 
dynamic interfacial tension can be measured as additional surfactant is adsorbed to the 
interface.  Because the PDPA technique assumes that the drop is static, low flow rates 
must be used if systemic errors are to be avoided.  Figure 3.13 shows drop volumetric 
flow rate and interfacial expansion rate as a function of time for eight individual drops, 
with time zero defined as the point of drop snap off for the previous drop.  Figure 3.14 
shows average interfacial tension (n = 11) and relative standard deviation (RSD) across 
the same data set.  As can be seen, the method is noisy for young drops, as measured by 
the RSD.  This is due to the small deformations in young drops, which results in highly 
spherical drops, a consequence of the small ratio of gravitational to interfacial forces. 
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Figure 3.13 – Volume and surface expansion rates during PDPA.  
These values are calculated for dispersed phase of a 9% solution of 
PLG in dichloromethane being pumped into a continuous phase of 1% 
poly(vinyl alcohol) in water.  The flow rate set point is 11.0 mL/hr and 
the needle size is 460 µm. 
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Figure 3.14 – Average interfacial tension (n = 11) (pink open 
squares) and associated relative standard deviation (blue closed 
diamonds) during PDPA.  The values are calculated from a series of 
images of 9% PLG in dichloromethane being dripped into a continuous 
phase of 1% poly(vinyl alcohol) in water.  The flow rate set point is 
11.0 mL/hr and the needle size is 460 µm.   
3.3.5 Drop Weight Method 
Before beginning, the phases are equilibrated in contact with each other.  As 
shown in Figure 3.9, a syringe pump is used to drip the DP into the CP at a controlled 
rate.  Videos of the dripping are recorded.  Droplet size is measured starting from high 
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contrast images of detached droplets, thresholding and converting the images to binary, 
then finding the edge coordinates, and numerically integrating the volume of the droplets 
by assuming axisymmetry.     
The interfacial tension is determined using the Harkins and Brown methodology3-
4.  A simple force balance predicts that the weight of a drop that falls from a needle tip is 
related to the interfacial tension according to  
 30 6
DgD πργπ Δ=  (3.11) 
However, this expression only holds true in the limit of D0 → 0, due to non-linear effects 
that occur during droplet snap-off.  For finite D0, it was shown by Harkins and Brown3 
that an empirical correction factor could be found.  Yildrim et al.4 refined this approach 
to a simple correlation 
 81.260.3Bo Φ=  (3.12) 
 
where the Bond number Bo = ΔρgD02/4γ and Φ is the dimensionless drop size Φ = 
0.62D0/D.  This expression can be further manipulated to yield 
 ( ) 81.2020 /266.0 DDgDργ Δ= . (3.13) 
Thus the interfacial tension γ between the two fluid phases can be calculated once the 
diameter D of the drop that falls is measured, assuming the density difference Δρ between 
the phases, gravitational acceleration g, and the needle diameter D0 are known.  Because 
the drops that fall are deformed due to gravity and hydrodynamic forces, the equivalent 
spherical diameter D is calculated from the volume V of the droplet according to 
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Generally speaking, the interfacial tension is a function of the time scale over 
which the measurement is performed.  When using the drop weight method, we are 
interested in how the interfacial tension varies with the drop period Δt.  The drop period 
is simply  
 
DPQ
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The volumetric flow rate is calculated by measuring the drop volume and the time 
between drop detachments, and this flow rate is compared to the set point of the syringe 
pump in order to assure that the process is at steady state. 
In order to measure interfacial tension using this method, the flow stream must be 
dripping and not jetting, thus implying We ≤ O(1), where O(1) means a number on the 
order of 1.  This occurs for 
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Setting We = 1 and then combining these relationships provides the appropriate scaling 
relationship for how droplet period changes with needle size: 
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This implies that as the needle diameter grows larger, the droplet period decreases.  But 
in order to maintain We constant, the volumetric flow rate must be increased quickly, 
with QDP ~ D01.5.  Figure 3.15 depicts these results. 
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Figure 3.15 – Calculated drop period and corresponding flow rate 
to maintain We = 0.1.  Calculations are for a fluid system with Δρ = 
330 kg/m3 and γ = 8 mN/m. 
3.3.6 Contact Angle Analysis 
Contact angles of the various fluids against strips of stainless steel are measured 
by first cleaning the membranes via sonication in a 1% Alconox solution, then thoroughly 
rinsing and drying.  The strips are then placed into a medium of one fluid, and the second 
fluid is dripped onto the surface of the strip.  The process is recorded using the video 
microscope, and the contact lines are observed until equilibrium is reached.  
Subsequently the images are analyzed via the DropSnake ImageJ plugin5, which utilizes 
Laplace's equation to find the contact angle which results in the best fit of the drop 
contour.  Depending on the preference for the outer phase (CP), either Method #1 or 
Method #2 is used, shown in Figure 3.16.  Independent of which fluid is selected as the 
CP, the contact angles in these two methods should be related according to θDP/SS = 180° 
– θCP/SS.  
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Figure 3.16 – Schematic of pendant or sessile drops during contact 
angle experiments.  The drops are attached to needle tips prior to 
dripping onto a stainless steel substrate. 
 
Figure 3.17 – Inverted image of water + 1% PVA on SS in a 
medium of DCM. 
3.4 Preliminary Results from Physical Property Measurements 
3.4.1 Interfacial tension measurements of normal alcohols 
The interfacial tension of n-alcohols against water were measured by Villers and 
Platten2 as a function of temperature using the Wilhelmy plate method, and these results 
are used for comparison to the PDPA results derived within this work.  Figure 3.18 shows 
the reported values of Villers and Platten for different n-alcohols containing between 4 
and 12 carbon atoms (solid line), as well as our results (diamonds).  The data are 
comparable, with the largest difference being for decanol, where the difference is about 
10%.  This difference could be caused by system impurities or subtle temperature 
differences.  Regardless, the differences across the range of compounds are small enough 
to conclude that the PDPA data are generally accurate. 
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Figure 3.18 – Comparison of experimental and reported values of 
interfacial tension at 20°C. 
3.4.2 Physical properties of binary solutions of n-hexanol and 
dichloromethane 
When examining the behavior of different fluids in the XME process, it is 
convenient to be able to tune physical properties through mixing two pure fluids.  As a 
DP, n-hexanol and dichloromethane have disparate properties, and thus display 
drastically different dynamics during dripping-jetting transitions and droplet snap off in 
XME.  Thus their mixtures are used to probe the transition between the different physical 
regimes.  The physical properties of the mixtures as a function of weight percentage of 
DCM are shown in the four plots contained within Figure 3.19, with the solid lines 
generated by applying a weighted average to the values for the pure components.  The 
density and viscosity of the mixtures show negative deviations from the interpolated 
predictions, which could be caused by a repulsive force between the two component 
molecules.  The interfacial tension against water, measured via PDPA, also shows a 
negative deviation, and the trend also shows strange curvature.  For this reason, replicate 
experiments were conducted, with the error bars indicating the standard deviation.  The 
error bars show that the data are reproducible, and any error must be systematic in nature.  
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It is likely that some systematic error is introduced because the density of the solution is 
near that of water, and this reduces the accuracy of the PDPA technique.  The fourth plot 
in Figure 3.19 shows the Ohnesorge number, Oh = µ/(ρD0γ)1/2, with D0 = 90 µm, as a 
function of concentration, and it can be seen that a wide range of Oh are accessible 
through the use of binary hexanol-DCM mixtures. 
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(c) Interfacial tension of mixtures against water (d) OhDP of mixtures with D0 = 90 µm 
Figure 3.19 – Physical properties of mixtures of n-hexanol and 
dichloromethane. 
3.4.3 Viscosity of polymer solutions 
When used as the dispersed phase in XME, the shear viscosity of the polymer 
solution has an appreciable impact on both the physics of droplet formation and break 
off, and also on the stability of droplets during downstream processing.  For these 
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reasons, we measure the relationship between polymer concentration and shear viscosity 
for both a binary solution of PLG in DCM, and a PLG:haloperidol in DCM ternary 
system.  Measurements are performed using capillary viscometry.  Using the values 
obtained for the shear viscosity of both the pure solvent η0 and the polymer solution η at a 
given polymer concentration c, we can calculate a number of other useful parameters that 
are widely used throughout the polymer literature.  Table 3.4 gives the definitions of 
these terms. 
Table 3.4 – Definitions of viscosity terms. 
Parameter Definition 
Relative viscosity 
0η
ηη =rel  
Reduced viscosity 
c
rel
red
1−
=
ηη  
iscosityInherent v  
c
rel
inh
)ln(ηη =  
 viscosityIntrinsic  [ ] redcinhc ηηη 00 limlim →→ ==  
 
Utilizing these definitions, we calculate both the inherent viscosity ηinh and reduced 
viscosity ηred as a function of polymer concentration.  At low concentrations, these 
relationships are both predicted to be linear.  Figure 3.20 shows that this is indeed the 
case for the binary system.  Both curves are predicted to intercept the y-axis at the 
intrinsic viscosity, [η], which we measure to be 57.3 mL/g.  The polymer overlap 
concentration, c*, is approximately equal to the reciprocal of this value, c* ≈  1/[η] = 
0.0175 g/mL.  The slope of the reduced viscosity curve is [η]2k', where k' is called the 
Huggins' coeffiecient.  For this system, k' = 0.44, and this value indicates that DCM is 
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neither a good solvent for PLG (0.3 < k' < 0.4) nor a theta solvent (0.8 > k' > 0.5), but 
rather is between these two extremes6.   
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Figure 3.20 – Viscosity dependence on polymer concentration for 
PLG dissolved in DCM. 
Above c*, ηred is often observed to rise exponentially in accordance with the Martin 
equation 
 [ ] [ ]( )ηηη kcred exp= . (3.18) 
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Figure 3.21 – Shear viscosity dependence on polymer concentration 
for PLG dissolved in DCM. 
In Figure 3.21, we plot the shear viscosity as a function of polymer concentration, 
and fit the data to the Martin equation using a non-linear least squares regression.  The 
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data fit well, despite the fact that only one fitting parameter is used.  Also shown on the 
plot are viscosities of the PLG:haloperidol 9:1 ternary solution.  The viscosities are 
similar, but systematically lower than the predictions for the binary system, most likely 
due to small temperature differences during the two experiments. 
3.4.4 Zimm theory 
In some experiments it is desirable to predict the polymer relaxation time λ while 
in solution.  In particular, this prediction is relevant to the dynamics of droplet neck snap 
off, where polymer molecules are elongated due to the high elongational stresses in the 
flow.  Zimm theory predicts that for dilute solutions, λ is related to the polymer and 
solution properties by   
 [ ]
RT
M w
2
06
π
ηηλ =  (3.19) 
where Mw is the polymer molecular weight (Mw = 137 000 g/mol for the PLG grade used 
here), and R and T are the gas constant and system temperature, respectively.  At 
concentrations higher than the dilute limit, this relation is often used as an estimate of λ, 
with the solvent viscosity η0 replaced by the solution viscosity η.7  The relaxation time in 
a standard 90% DCM, 9% PLG, and 1% haloperidol solution can then be estimated to be 
λ = 3 x 10-5 s.   By doubling c, we predict an increase from η = 15 mPa-s to 240 mPa-s, 
which would result in λ = 5 x 10-4 s, a 17-fold increase.  Similarly, by keeping 
concentration constant but instead doubling the molecular weight so that Mw = 274 000 
g/mol, we predict that [η] = 90 mL/g and η = 73 mPa-s.  Coincidently, this would also 
lead to λ = 5 x 10-4 s.  During a typical XME experiment using this ternary system, the 
strain rate is found to be ε&  = 2400 s-1, implying that the typical system will not exhibit 
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elastic effects, but that elastic effects should be found at higher Mw or c because De = ε& λ 
> 1.  These results are further discussed in Chapter 4. 
3.5 Sizing of Microspheres  
In most experiments, the droplets produced via XME are deformed from a sphere 
and into a prolate spheroid due to the shear stress imposed by the flowing CP.  This 
complicates slightly the measurement of particle size.  The diameter of a droplet is 
measured in two ways.   In the simplified method, the major and minor diameters are 
measured manually in ImageJ from a video frame containing the droplet image.  When 
higher resolution and/or larger sample sizes are needed, an automated image analysis 
routine in Matlab processes image sequences such that an ellipse can be fit to the droplet 
perimeter.  This image analysis process is similar to what is used for interfacial tension 
measurements.  Specifically, droplet images are converted to binary, thresholded, and the 
droplet edge coordinates are determined, from which the major and minor diameters and 
angle of rotation are determined.  In all cases, the reported diameter is calculated as the 
average of the major and minor diameters.  While an assumption that the particle takes 
the shape of a prolate spheroid with equivalent spherical diameter D = (Dminor2Dmajor)1/3 
may be more appropriate for highly deformed particles, for the small deformations seen 
here the result is indistinguishable from this and other advanced diameter calculation 
techniques. 
3.6 Downstream Processing of Drug and Polymer Loaded 
Emulsion Droplets 
The classical oil-in-water emulsion-solvent evaporation method is used in 
preparation of solid microspheres8.  After production of the emulsion droplets via XME, 
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they are collected in a large vessel and allowed to settle under gravity.  Only gentle 
agitation is used so as to prevent shear break up of the particles.  Over a period of many 
hours, DCM is slowly extracted into the CP, where it is sparingly soluble (solubility of 13 
g/L in pure DI water at 20°C).  The DCM is then readily evaporated from the collection 
vessel due to its low boiling point (vapor pressure of 47 kPa at 20°C), yielding solid 
drug-loaded polymer microspheres.  These solid microspheres are then isolated from the 
suspending medium by filtration, and in the process are washed with pure DI water to 
eliminate residual PVA. 
3.7 Computational Fluid Dynamics 
Two software programs, Fluent 6.3 and Gambit, are used to perform 
Computational Fluid Dynamics (CFD) simulations of the membrane emulsifier CP flow 
and the emulsification process.  
3.7.1 Continuous Phase Flow Simulations 
Although the velocity profile for fully developed laminar flow in a rectangular 
channel can be found analytically, it is difficult to assess whether flow is full developed 
when it passes the membrane pore.  CFD simulations of the velocity in the entire CP flow 
channel as a function of the total flow rate QCP yield the results shown in Figure 3.22.   In 
the simulations, ρ = 1020 kg/m3, µ = 0.0034 kg/m/s, and the simulation is set up using 
steady state,  three dimensional, double precision, pressure-based Navier-Stokes equation 
in laminar flow.  Boundary conditions are constant velocity at the inlet, and constant 
pressure at the outlet, with no slip at the chamber walls.  As can be seen, flow profiles at 
the y-z plane x = 0 are fully developed and symmetric for QCP = 10 mL/min and QCP = 
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100 mL/min, whereas at QCP = 1000 mL/min the flow is no longer well behaved.  
Consequently, experiments are conducted such that QCP < 300 mL/min. 
  
(a) Top View – 10 mL/min (b) Front View – 10 mL/min 
  
(c) Top View – 100 mL/min (d) Front View – 100 mL/min 
  
(e) Top View – 1000 mL/min (f) Front View – 1000 mL/min 
Figure 3.22 – Contours of velocity magnitude (m/s) calculated in 
Fluent 6.3.  Flow is in +x-direction. 
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3.7.2 Cross-flow membrane emulsification simulations 
Simulations of the cross-flow membrane emulsification process are performed to 
further validate experimental and theoretical results.  In the simulations, the 
computational mesh is set up with the following properties: 
• CP Zone (x by y by z) = 6.35 mm by 3.175 mm by 3.175 mm 
• DP Zone (diameter by length in y) = 0.090 mm by 0.3048 mm 
• Single x-y symmetry plane at pore midline z = 0 
• Number of cells = 6 x 105 
 
Figure 3.23 – Computational mesh used for CFD simulations of 
membrane emulsification. 
Fluid properties used in the simulations are shown in Table 3.5.  Through the 
simulations, the CP volumetric flow rate QCP is varied, while the DP flow rate QDP is held 
constant.  Simulation boundary conditions are constant velocity at both inlets, constant 
pressure at the outlet, and a contact angle of 180° between the DP and the chamber walls.  
Figure 3.24 shows typical results.   
Table 3.5 – Physical properties of fluids in Fluent simulation. 
Chamber Properties DP Properties CP Properties CP/DP 
D0 
(µm) 
H 
(mm) 
W 
(mm) 
ρ 
(kg/m3) 
μ 
(kg/m/s) 
ρ 
(kg/m3) 
μ 
(kg/m/s) 
γ 
(kg/s2) 
90 3.18 6.35 1326.5 0.000437 1000 0.00125 0.0061 
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Figure 3.24 – Volume fraction contours shown at the symmetry 
plane during a cross-flow membrane emulsification simulation.  In 
this simulation, QCP = 50 mL/min and QDP = 5.1 mL/hr. 
3.7.3 Cross-flow membrane emulsification simulation results 
Simulations are performed across the range 50 mL/min < QCP < 400 mL/min, and 
all at QDP = 5.1 mL/hr.  In each case, the simulation is run until a droplet breaks off from 
the membrane pore.  The image is then analyzed to determine the diameter of the droplet.  
The dimensionless droplet size D/D0 is plotted against the capillary number,  
 γμ 0Ddz
dvCa CP= . (3.20) 
A regression line fit to the data yields the form D/D0 = kCa-0.5, with k = 0.42. 
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Figure 3.25 – Dimensionless droplet diameter vs. capillary number 
from Fluent simulations. 
3.8 Model Drug Haloperidol 
Haloperidol is a popular drug indicated for use in the management of psychotic 
disorders, as well as for the control of tics of Tourette's Disorder9.  It is an excellent 
model drug for use in microencapsulation studies due to its low daily dose and high 
hydrophobicity10.  Furthermore, because the drug has been studied since at least 196011, it 
has been the subject of numerous investigations12-17, and physical and chemical properties 
are widely available.  For these reasons, haloperidol is used throughout the present 
studies. 
 
Figure 3.26 – Haloperidol molecular structure. 
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Table 3.6 – Physical and chemical properties of haloperidol. 
Property Value Units 
Molecular weight11 375.86 g/mol 
Crystalline melting point (free base)11 148 °C 
Water solubility at pH = 7.4 and room temperature17 15 mg/L 
Water solubility at pH = 6.0 and room temperature17 201 mg/L 
pKa17 8.25  
Peak UV absorbance18 244 nm 
Extinction coefficient at 244 nm18 0.0341 L/mg/cm
Typical oral dose range (BID or TID)9 0.5 – 5.0 mg 
Elimination half-life19 15.1 ± 2.5 hr 
Relative bioavailability19 0.64 ± 0.23  
3.9 In Vitro Drug Release Measurement System 
A dual reactor and flow system coupled to a dual inline spectrophotometer are 
used to measure drug release from polymer particles over time.    The two independent 
systems can be used to conduct two release studies simultaneously, or one can be used as 
a control or to continuously monitor background absorbance.  These components are 
described below. 
3.9.1 Drug release microenvironment 
A Spectra/Por Float-a-lyzer G2 1 mL dialysis device with 100K MWCO cellulose 
ester membrane (Sigma-Aldrich, St. Louis, MO) is used to retain the particles in a static 
state without convection during drug release studies, which is similar to the physiological 
environment particles experience when injected subcutaneously or intramuscularly.8  The 
particles are added to the container along with buffer solution, and a screw on cap with o-
ring positively seals the container.  A flotation ring surrounds the outside of the device 
and thus maintains the device oriented upright at the fluid surface within the stirred tank. 
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3.9.2 Reactor and Flow System 
Figure 3.27 shows a diagram of the system flow setup, which is designed as 
follows.  A recirculating controlled temperature water bath sends warm water through 
two daisy-chained glass jacketed mixing tanks, thus keeping the vessels at the desired 
temperature set point, typically 37°C.  The two mixing tanks are typically filled with 900 
mL phosphate buffered saline solution, and sometimes a surfactant such as polysorbate 
20, and an antimicrobial agent such as NaN3.  At the bottom of the tanks are magnetic stir  
bars, driven by the magnetic stir plates below.  Three through holes are cut into the 
custom-made lid for each vessel.  A long supply dip tube is located near the bottom of the 
vessel.  From the supply dip tube, silicone silastic tubing leads to the bottom of the quartz 
flow cell so that any air entrained in the system can escape.  The top of the flow cell is 
connected to Cole-Parmer Pharmed tubing, which is more resilient to continuous use.  
The tubing passes through the peristaltic pump, and then leads back to the return dip tube 
in the same mixing tank.  One ¼ inch diameter type K immersible thermocouple is 
located in each tank and is connected to the data acquisition system to provide continuous 
temperature monitoring. 
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Figure 3.27 – Reactor and flow system used for drug release 
studies. 
3.9.3 Dual-Channel Spectrophotometer 
The dual-channel spectrophotometer shown in Figure 3.28 can be used to measure 
the UV absorbance at λ = 250 nm of any solution contained in a standard 1 cm cuvette.  
The wavelength of 250 nm is used because there is a maximum in haloperidol absorption 
near this value (λmax = 244 nm).  Other wavelengths can be selected by replacing the 
band-pass filter that follows the collimating lens.   
The spectrophotometer is designed as follows.  A function generator is used to set 
the frequency with which light is produced.  Typically, a frequency of 1 pulse per second 
is used, and the monostable multivibrator 74HC123 chip is used to stretch the pulse to the 
desired width.  See Figure 3.29 for the circuit design.  The PX-2 UV (Ocean Optics, 
Dunedin, FL) light source produces a pulse of wide spectrum UV light when it detects the 
rising edge from a 0 to 5 V TTL signal from the peak-hold circuit.  After being 
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transmitted through a fiber optic cable, the light is collimated and passed through a 250 
nm band pass filter.  A polka dot beam splitter (Thorlabs, Newton, NJ) divides the 
collimated light beam into two roughly equal beams 90° apart.  Each collimated light 
beam passes through a quartz cuvette.  Glass absorbs UV light and thus cannot be used.  
Any absorbing species reduces the amount of light that is transmitted through the cell.  A 
40 mm focal length lens contained within a 1 inch diameter lens tube focuses each light 
beam onto the 2.54 x 2.54 mm active area on the PDA25K photodiode (Thorlabs).  The 
photodiode, set to a gain of 70dB, sends a 0 to 10 V signal to the LF398 chip on the peak-
hold circuit.  The signal output of the LF398 chip tracks the signal input from the 
photodiode as long as the logic input voltage to the chip is 5 V.  When the logic input 
falls to 0 V, the logic gate closes and the capacitor on the chip holds the signal output at 
the voltage read when the falling edge was detected.  The monostable multivibrator 
74HC123 is used to set the square wave pulse to the desired width, such that the falling 
edge corresponds with the peak output from the photodiode.   The OMB-DAQ USB data 
acquisition module reads the signal output voltage on the LF398 chip and records to a 
Microsoft Excel file.  The signal output reads the peak of the photodiode signal except 
when the TTL signal is at 5 V.  Because this only occurs for about 10 µs every second, 
this is a rare occurrence.  The peak hold circuit shown in Figure 3.29 is used to collect the 
photodiode signal and transmit it to the data acquisition device. 
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Figure 3.28 – Spectrophotometer optics and electronics 
configuration. 
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Figure 3.29 – Timing circuit and peak-hold circuit used within the 
spectrophotometer. 
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The photodiode gives readings in voltage, and the absorbance A is calculated 
using 
 ⎟⎠
⎞⎜⎝
⎛
=
V
VA 0log  (3.21) 
where V is the reading of the sample, and V0 is the reading of the cell with solvent (but no 
sample).  Beer's Law states that  
 LcA iiε=  (3.22) 
where εi is the extinction coefficient of species i, ci is the solute concentration, and L is 
the cell path length.  Using these relationships, the concentration of dissolved species can 
be determined from the absorbance readings once the absorption coefficient is known.  A 
calibration curve generated using numerous dilutions of a 50 mg/L haloperidol in 0.1% 
lactic acid aqueous solution shows that Beer's law holds true up to at least c = 50 mg/L, 
and the limit of detection for haloperidol is around c = 0.1 mg/L. 
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Figure 3.30 – Calibration curve of spectrophotometers using 
haloperidol. 
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3.9.4 Pure haloperidol dissolution experimental results 
To test the reactor and flow system, we measure the dissolution of haloperidol in 
phosphate buffered saline (PBS) containing 0.02% sodium azide and 1% polysorbate 20 
at a temperature of 37°C.  Because the system is not closed during the experiment, we 
observe significant evaporation from the vessels, which are at elevated temperature.  For 
this reason, the second parallel spectrometer is used as a baseline throughout the 
experiment.  The photodiode gives readings in voltage, and the absorbance value is 
calculated using A = -log(V1/( V2–V2,0+V1,0)), where V1 is the reading of the sample in 
system #1, V2 is the reading of flow system #2, and Vi,0 is the initial reading in each 
system.  After preparing the solution as described and heating to the proper temperature, 
we sprinkle ~100 mg of haloperidol on top of the stirring tank. 
The dissolution results are shown in Figure 3.31.  The experimental data are fit to 
a standard exponential curve 
 ( )( )τ/exp1/ lagttcc −−−=∞  (3.23) 
with c∞ = 9.90 mg/L, tlag = 0 hr, and τ = 4.60 hr.  Surprisingly, the experiment did not 
show any increase in the equilibrium solubility of haloperidol compared to pure PBS at 
37°C, which has previously been measured as ~10 mg/L (data not shown).  However, the 
rate at which equilibrium is reached is faster than previous experiments.  This is likely 
caused by improved wetting of the haloperidol particles due to the presence of the 
surfactant in the system. 
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Figure 3.31 – Haloperidol dissolution into PBS at 37°C with 0.02% 
sodium azide and 1% polysorbate 20. 
3.10 Mathematics of Fluid Flow Through a Rectangular Channel 
Because the CP travels in laminar flow down a long rectangular channel through 
the membrane emulsifier, it is important to understand the mathematics that describe the 
flow profile.  Figure 3.32 describes the geometry. 
y H = 2b
z 
W = 2a  
Figure 3.32 – Geometry of a rectangular channel. 
For Newtonian fluids in fully developed laminar flow, solving the Navier-Stokes 
equation results in the following expression for the fluid velocity vx in the x-direction as a 
function of position in the y and z directions.  
 ( )
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 65
However, because of the slow convergence of this infinite series, it is much more 
convenient to work with an approximate solution.  Purday proposed the following 
expression20 
 ⎥⎥⎦
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⎛
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with the parameter α defined as 
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The maximum velocity vx can be related to the total volumetric flow rate QCP through 
integration 
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which yields 
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12
3
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α  (3.28) 
To test the accuracy of the Purday approximation, we plot both the full solution 
and the approximate solution at the channel center for the two different channel heights 
used in this research, and Figure 3.33 is the result.  As can be seen, there are only 
negligible differences in the two equations for the set of parameters studied here. 
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Figure 3.33 – Velocity profiles calculated for flow in a rectangular 
duct.  Solid lines give the profile from the full analytical solution, 
while dotted lines give the approximate solution of Purday.  Shown are 
the velocity profiles for the two channel heights used in our study, b = 
H/2 = 1.59 mm and b = 0.50 mm. 
Ultimately, we are interested in the shear rate at the membrane pore, which can be 
calculated through differentiating the velocity profile from the Purday equation 
 ⎟⎠
⎞⎜⎝
⎛ +
=⎟⎠
⎞⎜⎝
⎛
m
m
WH
Q
dz
dv
pore
16
2
CP  (3.29) 
For the special case of 1 < W/H < 3, an alternate expression for the shear rate was derived 
from the full analytical solution, and this expression in included here for completeness. 
 33.167.1
CP7.9
WH
Q
dz
dv
pore
=⎟⎠
⎞⎜⎝
⎛  (3.30) 
Either expression can be used within the specified limits, but in general the expression 
derived from the Purday equation is preferred due to wider applicability. 
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Chapter 4: Universal dripping and jetting in a transverse 
shear flow 
One particularly efficient approach to making emulsions having mono-sized 
droplets is to push a fluid through an orifice into a transverse flow of a second immiscible 
fluid. We find that at intermediate particle Reynolds number, the final droplet size can be 
readily computed using a simple force balance. Remarkably like the well-known dripping 
faucet, this system displays both dripping and jetting behavior, controlled by the 
capillary, Weber and Ohnesorge numbers of the relevant fluids, and interesting non-linear 
behavior such as period doubling near the transition between these two regimes. 
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4.1 Introduction 
Drop formation and breakup have long been an object of interest due to the 
surprising complexity of the phenomena1. Breakup occurs either by an external force 
tearing a growing drop from an orifice, as in the dripping faucet, or at higher flow rates, 
by the breakup of a jet emerging from the orifice, as in the Rayleigh instability2. Near the 
transition between dripping and jetting, drop formation shows interesting non-linear 
dynamics, including period doubling and chaos3-4. More recent studies have probed drop 
formation in several microfluidic geometries, such as coaxial flow5-6 and T-junctions7, 
where controlled droplet formation is an important technological problem. 
Here, we study droplet formation in a cross-flow membrane emulsification 
(XME) geometry, a high-throughput method for generating mono-disperse droplets8-10. In 
XME, the dispersed phase (DP) is forced through an orifice in a planar membrane into a 
simple shear flow set up by a second continuous phase (CP) flowing parallel to the 
membrane surface, see Figure 4.1(a). In the dripping regime, when buoyancy forces are 
negligible11, the final droplet diameter, D, results from the competition between 
hydrodynamic stresses proportional to the CP shear rate, dv/dz, and forces from the 
interfacial tension, γ. This leads us to introduce the capillary number, which is a ratio of a 
drag force, μCP(dv/dz)D02, and an interfacial tension force, γD0: Ca = μCP(dv/dz)D0/γ, 
where μ is the viscosity and D0 the orifice diameter. At high DP flow rates, the inertial 
force of the fluid emerging from the orifice, ρDPQDP2/D02, exceeds the interfacial tension 
force, leading to a transition to jetting behavior, where Q is the volumetric flow rate and 
ρ the mass density. The ratio of these forces is the Weber number: We = ρDPQDP2/D03γ. 
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We find that the droplet size in the dripping regime scales with the applied forces in a 
manner different from those in the dripping faucet and coaxial flow geometries, but that 
the transition between dripping and jetting is remarkably similar. This latter point is more 
surprising given the lack of axial symmetry in our system. 
4.2 Methods 
Our experimental apparatus consists of a long rectangular channel with height H = 
3.2mm and width W = 6.4mm through which the CP flows. The DP is forced through a 
single circular pore (D0 = 15, 90 or 132µm) on the centerline of the bottom wall, using a 
syringe pump. Drop formation is monitored from the side, with a viewing angle ≈ 7° 
above the membrane plane, using a long-working distance video microscope. A pair of 
right angle prisms straddling the channel redirects illumination and viewing light through 
a window at the top of the channel. Several fluids were used for the DP, listed in Table 
4.1, while the CP was limited to water, sometimes with poly(vinyl alcohol) (PVA) as a 
surfactant. For each system studied, the two fluids were equilibrated in contact, so as to 
minimize mass transfer during the experiment. The densities ρCP and ρDP, viscosities μCP 
and μDP and interfacial tension γ for each equilibrated combination were measured 
directly by mass, capillary viscometry and pendant drop profilometry12, respectively (cf. 
Table 4.1).  
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Table 4.1 – Liquids used and some of their physical properties at 18°C.  Mixture proportions are given 
in w/w. Small, medium and large symbols represent a D0 of 15, 90 or 132µm, respectively. 
Dispersed Phase 
(surfactant) 
ρDP 
(kg/m3) 
μDP 
(mPa s) 
γ 
(mN/m) 
Symbol 
n-butanol 827 3.31 2.4  
n-pentanol 817 3.61 4.8  
n-hexanol 809 5.06 6.3  
DCMa + hexanol 20/80 871 3.12 7.5  
DCM + hexanol 40/60 943 1.79 9.7  
DCM + hexanol 60/40 1039 1.14 9.1  
DCM (0.05% PVA) 1320 0.44 12.0  
DCM (0.50% PVA) 1320 0.44 6.1  
DCM (0.50% PVA)b 1320 0.44 6.1  
ethyl acetate 902 0.50 6.5  
adichloromethane, bcomputational fluid dynamics simulation15 
4.3 Qualitative results 
The qualitative features of the dripping and jetting behavior in XME are shown by 
the images in Figure 4.1, taken at a constant Ca. At low Weber number, We = 0.5, simple 
dripping is observed, Figure 4.1(b-d). Because the interfacial force is dominant, the 
droplet is able to grow reproducibly each cycle until detached by the flowing CP. At We 
= 1.1, the location of droplet snap-off moves away from the orifice, but the size of the 
resultant droplet remains roughly the same, Figure 4.1(e-g). The momentum of the 
flowing DP distends the droplet neck noticeably; for these parameters the distended neck 
also snaps-off reproducibly to form a satellite droplet. Increasing the DP flow rate further 
by 20%, We = 1.6, causes further extension of the droplet neck, with multiple peaks and 
nodes observed, and a noticeable decrease in droplet size, Figure 4.1(h-j). An additional 
10% increase in QDP, We = 2.0, leads to a stable bifurcation of the resultant droplet size, 
where the elongated neck/jet alternates production of small and large droplets, Figure 
4.1(k-m). These and more complex non-linear dynamical behavior (not shown) were 
observed near the transition, over the entire range of different Ca we studied. 
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Figure 4.1 – Dripping and jetting at various We for Ca = 8 x 10-4 
and OhDP = 4 x 10-2, variables defined in text. (a) Cartoon 
representation of the XME process, where droplets of dispersed phase 
(DP) are torn from an orifice by a simple shear flow in the continuous 
phase (CP). At low DP flow rates, monodisperse drops form and break 
off near the pore (b-d); scale bar = 500 µm. As the DP flow is 
increased, first droplets are the same size, but move away from the pore 
prior to snap-off, forming satellite drops (e-g). Eventually, the fluid 
neck lengthens further and droplet sizes decrease (h-j). Ultimately, a 
bent fluid jet breaks into droplets, exhibiting period doubling (k-m).  
4.4 Development of droplet size model 
Given the interest in using XME to produce monodisperse emulsions, we first 
seek to understand the particle size in the dripping regime (i.e. low We), as a function of 
the hydrodynamic stress due to the shear flow; typical data are shown in Figure 4.2(a). 
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For all systems studied, the droplet diameter scales as D ∝  (dv/dz)-1/2. This square root 
dependence has a simple physical origin. In our geometry, the mean velocity of the fluid 
at the drop center is itself proportional to the droplet size, as larger droplets poke up 
higher to impinge on faster flows, leading the hydrodynamic stress to depend 
quadratically on the droplet diameter. Equating that hydrodynamic stress with a constant, 
maximal interfacial tension at snap-off trivially yields the desired scaling exponent. 
To make such a force balance relation more precise, we begin by equating the 
drag force Fd with the interfacial tension force Fγ at the moment of snap-off 
 γπρπ 0γ22CPdd 8
DFDvCF ===
∞
, (4.1) 
where v∞ is the far-field velocity at droplet midline and Cd = Cd(Rep,λ) is the drag 
coefficient for a spherical droplet with particle Reynolds number Rep = ρCPv∞D/μCP and 
viscosity ratio λ = μDP/μCP. Eq. (4.1) can be rearranged as 
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where we have introduced the CP Ohnesorge number, OhCP = μCP/(ρCPD0γ)1/2, which is a 
ratio of viscous and capillary time scales. Solving Eq. (4.2) for the droplet diameter is not 
trivial since Rep and Cd depend on D. Careful examination of Eq. (4.2) reveals that Rep at 
snap-off is independent of Ca, and a function only of material properties and the pore 
size. Substituting the approximation v∞ = (D/2)(dv/dz) and rearranging dimensionless 
groups yields: 
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 ( ){ } 2/12/12/1CP4/1d0 /32/ −− == kCaCaOhCDD , (4.3) 
where we have introduced k for the prefactor in braces. The parameter k is nearly 
independent of Ca, and depends almost entirely on CP properties, with the only DP 
contribution coming from the viscosity ratio λ. Because of the small exponents on Cd and 
OhCP, k varies little over a wide variety of fluid-fluid systems. This corresponds to the 
earlier mentioned square root scaling with shear rate, as Ca ∝  dv/dz.  
For creeping flows, Rep < 1, Eq. (4.3) can be solved by substituting the Hadamard 
and Rybczynski relation13,  Cd = [8(3λ+2)/(1+ λ)]Rep-1, which was derived for liquid 
spheres in a shear flow (in the absence of a wall), canceling OhCP  
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Thus, for small pores and slow flows, we can derive an exact force balance expression for 
D/D0. The Rep in our experiments, however, ranges from 2 < Rep < 150, so we solve Eq. 
(4.3) iteratively using an expression for Cd given by Saboni and Alexandrova13 
appropriate for our intermediate Rep case, which amounts to a 35% correction in the drop 
diameter for the highest Rep. Moreover, we compute the shear rate from our measured 
volumetric flow rate, QCP, using an analytical solution by White14, to derive the 
expression dv/dz = 9.7QCP/H1.67W1.33.  
Figure 4.2(b) shows the Ca dependent droplet size data, rescaled as (1/k)D/D0. If 
our force balance were exact, the data would fall along the line (1/k)D/D0 = Ca-1/2. This 
procedure does collapse the droplet size data, with a residual spread in normalized drop 
sizes of about 10% across all the fluid systems studied. The collapsed data, however, fall 
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systematically below the expected curve by about 20%. To investigate this discrepancy, 
we simulated the XME process using computational fluid dynamics15-16. The simulation 
results, also plotted in Figure 4.2(b) with the symbol ( ), show excellent agreement with 
the experimental findings. Thus, the discrepancy is presumed due to the simplifying 
assumptions made in the force balance, e.g. neglecting the hydrodynamic effect of the 
membrane17, assuming that the drag force acts perfectly antiparallel to the interfacial 
tension force, or neglecting neck effects similar to those in the dripping faucet18. To 
predict the XME droplet size a priori, one should use a value about 80% of that predicted 
by Eq. (4.3).  
 
Figure 4.2 – (a) Droplet diameter D versus shear rate dv/dz for all 
fluid systems, and (b) Collapse of scaled droplet size (1/k)D/D0 as a 
function of Ca, with k calculated from Eq. (4.3). The collapsed 
experimental data fall roughly 20% lower than the force-balance 
prediction (solid line), comparable to results from computational fluid 
dynamics ( ). See Table 4.1 for symbol definitions. 
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4.5 Modeling of the dripping-jetting transition 
Next we construct phase diagrams that delimit where dripping and jetting occur as 
a function of We and Ca, shown in Figure 4.4(a,c). We define jetting as occurring when 
the length of the neck, Ln, at snap-off exceeds the droplet diameter: Ln/D > 1, which 
correlates with large changes in D/D0 over the range of Ca studied, cf. Figure 4.3. A 
similar criterion is used in the dripping faucet literature19. At sufficiently low We and Ca, 
dripping is always observed, and as either is increased, the behavior will eventually 
transition to jetting. Qualitatively, these phase diagrams exhibit the same form as those 
for coaxial liquid streams5 and dripping faucets20, at least when Ca is substituted for the 
Bond number Bo in the latter case.11  In retrospect, one could have anticipated that jetting 
will occur whenever the force causing surface extension exceeds that causing surface 
contraction. This will happen independent of whether that force comes from the kinetic 
energy of the DP, the drag from the flowing CP, or from gravity. The transition, however, 
does not occur at the same location in Ca-We space for all fluid systems, rather, it is also 
controlled by the DP Ohnesorge number, OhDP = μDP/(ρDPD0γ)1/2. Figure 4.4(b) shows 
how the transition varies in We-OhDP space at low Ca, and again we find remarkable 
similarity to what has been observed in the dripping faucet geometry19. 
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Figure 4.3 – (a) Increase in neck length Ln relative to droplet 
diameter D as We is increased, and (b) corresponding decrease in 
droplet diameter ratio D/D0 as the dripping-jetting transition Ln/D 
= 1 is exceeded.  Neck length Ln always grows near the transition, and 
D/D0 subsequently varies (but does not always decrease) from the 
stable size observed in the dripping regime.  See Table 4.1 for symbol 
definitions. 
In the dripping faucet, the separatrix between dripping and jetting has been 
determined. Clanet and Lasheras derived an analytical expression20 to describe the 
dripping-jetting transition in We-Bo space when OhDP →  0. For finite OhDP, their 
expression quantitatively describes our low and high OhDP data when their We and Bo are 
replaced by a rescaled We and Ca, respectively, as shown by the solid lines in Figure 
4.4(a) and Figure 4.4(c). Similarly, Ambravaneswaran et al. generated a phase diagram in 
We-OhDP space at fixed Bo through numerical simulations19; their data are reasonably 
well described by a two-segment piecewise power-law in OhDP (corresponding to the 
inviscid and finite μDP limits). Again, this expression describes our data when OhDP is 
rescaled; the solid line in Figure 4.4(b) shows this result. We find that the product of 
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these two functions (with rescaled Ca and OhDP) describes our dripping-jetting transition 
surface in Ca-OhDP-We space: 
 [ ]{ }2/122222DP1 1)1(1)( −+−+= − CacCacOhcWe α , (4.5) 
where c2 = 860, and c1 = 0.10 and α = 0.89 for OhDP ≥ 0.03, or c1 = 2.27 = (0.10)(0.03)-
0.89 and α = 0 for OhDP < 0.03, as determined by least squares minimization. This surface 
is plotted in Figure 4.4(d). 
 
Figure 4.4 – Dripping to jetting phase behavior as a function of We, 
Ca and OhDP. Dripping is indicated by open symbols, jetting by filled 
symbols. In (a) and (c), which plot the same region of Ca-We space at 
different OhDP, jetting is always seen at sufficiently high values of 
either We or Ca. The transition curve, shown by the solid lines, is a 
function of OhDP and moves downward as OhDP is increased. In (b), 
viewing the data in OhDP-We space highlights the OhDP dependence (at 
low Ca). In (d), the surface separating dripping and jetting regimes, 
based on Eq. (4.5), is adapted from the references.19-20. Jetting can also 
be observed below this surface if the predicted droplet size is D/D0<2, 
not shown. See Table 4.1 for symbol definitions. 
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We also observe another dripping to jetting transition mechanism. Even at small 
Ca and We, under conditions where Eq. (4.3) predicts droplet sizes below the Rayleigh 
limit D/D0 ≈  2, dripping gives way to a jet running tangent to the membrane, without 
apparently wetting it. In this case, the jet breaks up downstream to yield droplets of size 
D/D0 ≈  2. This condition resembles operating conditions that prevail during 
emulsification in T-junctions7. Taken with the preceding result, the (Ca, OhDP, We) triple 
appears sufficient to determine whether dripping or jetting will occur during any XME 
process.  
4.6 Summary 
Dripping, jetting and the transition between them show remarkably similar 
characteristics in radically different geometries. Indeed, we were even able to adapt and 
analytically extend functional forms derived for the transition in faucets to the XME 
geometry with simple rescaling of the groups. Less surprising, the geometric details 
influence the relationship between droplet size and the relevant dimensionless groups. In 
the cross-flow membrane geometry as in the others, a force balance suffices for a precise 
prediction of droplet size as a function of process conditions. It seems likely that such 
relationships prevail in other microfluidic geometries as well. It remains unknown to 
what extent the lack of axisymmetry in our geometry affects the hydrodynamic 
singularity at the moment of snap-off21, or how the process is modified by non-
Newtonian fluid behaviors such as extensional elasticity22. 
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Chapter 5: Producing Monodisperse Drug-Loaded 
Polymer Microspheres via Cross-Flow Membrane 
Emulsification: The Effects of Polymers and Surfactants  
Cross-flow membrane emulsification (XME) is a method for producing highly 
uniform droplets by forcing a fluid through a small orifice into a transverse flow of a 
second, immiscible fluid.  We investigate the feasibility of using XME to produce 
monodisperse solid microspheres made of a hydrolysable polymer and a hydrophobic 
drug, a model system for depot drug delivery applications. This entails the emulsification 
of a drug and polymer-loaded volatile solvent into water followed by evaporation of the 
solvent. We use a unique side-view visualization technique to observe the details of 
emulsion droplet production, providing direct information regarding droplet size, 
dripping frequency, wetting of the membrane surface by the two phases, neck thinning 
during droplet break off, and droplet deformation before and after break off. To probe the 
effects that dissolved polymers, surfactants, and dynamic interfacial tension may have on 
droplet production, we compare our results to a polymer and surfactant-free fluid system 
with closely matched physical properties.  Comparing the two systems, we find little 
difference in the variation of particle size as a function of continuous phase flow rate.  In 
contrast, at low dripping frequencies, dynamic interfacial tension causes the particle size 
to vary significantly with drip frequency, which is not seen in simple fluids. No effects 
due to shear thinning or fluid elasticity are detected.  Overall, we find no significant 
impediments to the application of XME to forming highly uniform drug-loaded 
microspheres. 
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5.1 Introduction 
Emulsion-based materials have a diverse set of applications across many fields 
including electronics, cosmetics, foods, and pharmaceuticals1. In controlled release drug 
delivery applications, it has been shown that particles generated from monodisperse 
emulsions have well defined drug release rates, and thus particle size can be used to 
engineer improved formulations that deliver drug in a predetermined manner2-3.  Methods 
for producing monodisperse emulsions have been a popular topic of investigation in 
recent years, employing techniques such as flow focusing4, shear rupturing5, acoustic 
excitation6, microfluidic T-junction emulsification7, and membrane emulsification8. 
Membrane emulsification describes a wide variety of techniques whereby a dispersed 
phase (DP) is forced through an orifice in a membrane into an immiscible continuous 
phase (CP), thereby generating an emulsion.  To date, researchers have investigated the 
impact of the type of membrane and pore used, the method for detaching emulsion 
droplets, and the geometry in which the droplets are formed1, 9-10.   
We focus on cross-flow membrane emulsification (XME), due to the wide 
adjustability of particle size and the potential for high production rates through the use of 
multiple orifices in one device.  In XME, nascent droplets are formed at the membrane 
pore while subjected to a transverse shear flow, as shown in Figure 5.1(a).  The drag 
force exerted by the CP increases as the drop grows larger, until such point that the 
interfacial tension force can no longer hold onto the drop, and the process begins anew.  
It is this balance of drag and interfacial tension forces which allows for precise control 
over the size of the droplets which are produced, as we showed recently in simple 
fluids11. 
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Figure 5.1 –  (a) Schematic of the XME process and the important 
parameters, and (b) scale rendering of the CP fluid channel, 
membrane and optical path.  All components are contained within a 
machined aluminum carrier which is not shown. 
For many practical applications, including the production of drug-loaded 
microspheres12, emulsions must contain polymers,  surfactants, and other substances 
which introduce non-idealities into the system's fluid mechanics.  In this work, we 
examine the feasibility of using XME to generate such drug-loaded particles.  
Specifically, we investigate whether non-Newtonian viscosity, elasticity, and dynamic 
interfacial tension modify the XME process in an observable way, largely by comparing 
the drug and polymer-loaded system to a simple fluid system with similar physical 
properties.  Next, we investigate operational aspects related to the production of particles, 
including the uniformity of particles produced.  Finally, we explore droplet deformation 
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and rupture which can occur after particle generation but prior to drying, and result in 
size distributions of lower uniformity. 
5.2 Background 
 Because membrane emulsification has received significant attention in 
recent years, considerable background can be found in recent review papers1, 9-10, 12.  
XME in particular was studied experimentally by Peng and Williams13, and numerically 
by Abrahamse, et al.14  The effect of dynamic interfacial tension on XME was studied by 
van der Graaf, et al.15, but their study did not show a clear relationship between droplet 
production rate, the interfacial tension at that rate, and the resultant droplet size.  Using a 
T-shaped microchannel geometry, Husny and Cooper-White16 demonstrated the 
substantial consequences fluid elasticity has on droplet production, including long-lived 
droplet necks and abundant satellite droplets.  However, this study used a DP of water 
with dilute concentrations of high molecular weight poly(ethylene oxide), which is well 
known to exhibit elastic effects, and was not oriented towards manufacturing solid 
particles.  Preparation of PLG particles using stirred cell membrane emulsification was 
performed by Gasparini et al.17, and this study investigated many aspects of the process, 
including formulation variables and the drying procedure, but the study generated fairly 
polydisperse particles and did not investigate the physics of the emulsification process 
itself.   
In our earlier study in pure fluids11, we found two distinct processing regimes: 
dripping and jetting.  When the DP volumetric flow rate, QDP, is sufficiently low, the 
system will drip, and droplets of constant size are formed and detach near the membrane 
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pore.  The final droplet diameter, D, decreases in relation to the magnitude of the shear 
stress, which is proportional to the CP viscosity, μCP, and the CP shear rate, dv/dz.  
Conversely, D increases in relation to the interfacial tension, γ, and the pore diameter, D0.  
This leads us to introduce the capillary number Ca, which is a ratio of these drag and 
interfacial forces: Ca = μCP(dv/dz)D0/γ.  These are the only two significant forces present 
as long as buoyancy is negligible, which is the case for the small droplets studied here.  
At higher QDP, the inertia of the DP can no longer be neglected.  A jet forms, and the jet 
breaks into rather polysdisperse droplets far from the membrane pore due to the Rayleigh 
instability18.  The system gets closer to jetting with increasing inertial force of the DP, 
ρDPQDP2/D02, where ρDP is the DP mass density.  However, the tendency to jet is 
decreased by the interfacial tension force, γD0.  Thus we are interested also in the ratio of 
these forces, which is the Weber number, We = ρDPQDP2/D03γ.   
For a system consisting of pure fluids, we can use dimensional analysis19 to 
determine the dimensionless groups other than Ca and We which might be useful for 
study.  In XME there are 5 physical properties, 2 flow rates, and 2 length scales that are 
relevant.  Since these contain the dimensions of length, mass and time, there should be at 
most 9 – 3 = 6 independent dimensionless groups.  It is intuitive that the droplet diameter 
ratio D/D0 is a function of We and Ca, but dimensional analysis indicates that there are 
three additional dimensionless groups present.  These can be chosen as a viscosity ratio λ 
= μDP/μCP, and two Ohnesorge numbers, OhCP and OhDP, where Oh = μ/(ρD0γ)1/2.  The 
Ohnesorge numbers for each phase are a ratio of viscous and capillary time scales within 
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that phase.  Thus it is expected that D/D0 = f(Ca, We, OhDP, OhCP, λ).  In practice, it has 
been shown that for systems of low to moderate OhDP operating at low We11: 
 
D
D0
= k0Ca
−1/ 2  (5.1) 
where k0 is a function of physical properties and length scales alone, and can be treated as 
a constant within a given experiment.  The value of k0 can be calculated according to 
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In the preceding expression, Cd is the drag coefficient for the droplet in the cross-flowing 
CP, and can be estimated from empirical correlations20 which relate to the Reynolds 
number Re = ρvCPD/μ, and the viscosity ratio λ: 
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This expression, derived for fluid spheres in an external flow (in the absence of a wall) is 
accurate for 0.01 < Re < 400 and any viscosity ratio.  It should be noted that Re is not an 
independent dimensionless group, and can be expressed in terms of the other groups 
previously discussed, Re = CaOhCP-2(D/D0)2.     
5.3 Methods 
5.3.1 Experimental Apparatus 
 Figure 5.1(a) shows a schematic of the XME process, and Figure 5.1(b) shows an 
isometric drawing of the interior of the apparatus used in these experiments.  The 
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membrane holder is constructed from aluminum stock, and consists of a top and bottom 
half, between which the membrane is sandwiched.  CP is pushed from a pressurized tank 
through a flowmeter (FMTE4, DEA Engineering, Anza, CA) and into the membrane 
holder from the bottom.  DP is pumped into the bottom of the membrane holder using a 
syringe pump (Model 11 Plus, Harvard Apparatus, Harvard MA).  The pressures of both 
CP and DP are measured via pressure transducers (SPT4V, Invensys, Milpitas, CA).  
After changing direction, the CP flows along the membrane surface down a long 
rectangular channel 6.4mm wide by 3.2mm high.  In some experiments, a solid  insert is 
placed in the channel to decrease the height to 1.0mm.  In the center of the channel, DP 
passes through the membrane and into the cross-flowing CP, generating a droplet.  The 
emulsion then travels down the remainder of the channel, and exits the membrane holder 
at the bottom, and finally proceeds to the collection vessel. 
5.3.2 Membranes 
Disk-shaped membranes are constructed of stainless steel and cut to 50mm in 
diameter from 0.30mm thick sheet stock.  For each membrane, a single pore is cut into 
the center of the membrane using one of three methods: laser drilling (Oxford Lasers, 
Shirley, MA), mechanical drilling (Roland Research Devices, Trenton, NJ), or electrical 
discharge machining (EDM) (Makino / Hummingbird Precision Machine Co., Lacey, 
WA).  Electron micrographs showing the pores made via the various methods are 
provided in Figure 5.2.  For the majority of the studies, the mechanically drilled 
membrane shown in Figure 5.2(c) is used, because of the membrane's favorable wetting 
properties. Wetting of the membrane by the DP, readily visualized in our apparatus, can 
lead to a larger effective orifice size, and correspondingly anomalous droplet sizes. The 
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EDM membrane in Figure 5.2(b) is used for the mass-produced particles shown in Figure 
12, while the laser drilled membrane in Figure 5.2(a) is not used in the present work, but 
is shown for comparison purposes. 
 
Figure 5.2 – Membranes manufactured via different methods.  
Parts (a), (b) and (c) show stainless steel membranes of varying pore 
diameters, manufactured using laser drilling, electrical discharge 
machining (EDM), and mechanical drilling, respectively. 
5.3.3 Video Microscopy 
During production of the emulsion droplets, the process is observed from the side 
of the channel, through the use of two 1/8" right-angle prisms (Thorlabs, Newton, NJ) 
flush mounted in the channel wall.  Light is directed from above into the first prism, 
where it is then reflected through the droplet-forming region and into the second prism.  
The second prism subsequently reflects the light up through a long working distance 
video microscope and into a CCD camera (COHU 4915, San Diego, CA) collecting 30 
interlaced frames per second at 640 x 480 resolution.   Video images are collected using 
Video Toolbox (version 1.65, Zarbeco, Randolph, NJ), processed using VirtualDub 
(version 1.6.19, virtualdub.org), and analyzed using ImageJ (version 1.38x, 
rsb.info.nih.gov) and Matlab (R2007a, The Mathworks, Natick, MA). 
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Figure 5.3 – Example images of PLG droplets.  The side view set up 
allows for observation of phenomena not observable from above, such 
as wetting of the membrane surface, thinning of the droplet neck during 
break-off, and droplet deformation due to the shear flow. 
5.3.4 Materials 
When generating drug loaded polymer microspheres, the DP consists of the 
solvent dichloromethane (DCM), the biodegradable polymer poly(D,L-lactide-co-
glycolide) (PLG), and haloperidol as a model drug.  DCM was obtained from Fisher 
Scientific (Fairlawn, NJ).  PLG (50:50 D,L-lactide:glycolide, ester terminated, inherent 
viscosity = 0.82dL/g in HFIP) was obtained from Birmingham Polymers (Pelham, AL).  
Haloperidol was obtained from Sigma (St. Louis, MO).  The CP consists of the surfactant 
poly(vinyl alcohol) (PVA) dissolved in deionized (DI) water.  PVA (22kDa, 88% 
hydrolyzed) was obtained from Acros Organics (New Jersey, USA).  DI water (18 
MΩ/cm, Easypure Barnstead) was used throughout this study.  For comparison to ideal 
fluids, 1-decanol (Acros Organics) acts as the DP, and the CP consists of DI water. 
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Table 5.1 – Formulations of decanol and polymer-loaded systems. 
System CP DP 
Decanol DI water decanol 
Polymer 99% DI water 1% PVA 
90% DCM 
9% PLG 
1% haloperidol 
5.3.5 Preparation of CP and DP 
For the production of polymer microspheres, CP is prepared by dissolving PVA in 
warm DI water at a concentration of 1% by weight.  After dissolution of the PVA, the 
solution is filtered through a 14µm cellulose acetate filter and allowed to cool to room 
temperature.  DP is prepared by mixing haloperidol, PLG and DCM in a closed container 
overnight.  In most experiments, the DP contained 9% PLG and 1% haloperidol on a 
weight basis, and in one experiment, the concentrations were raised to 11% PLG and 
1.2% haloperidol so that droplets could be collected and dried without affecting the 
particle size distribution.   
5.3.6 Microsphere Drying 
The classical oil-in-water emulsion-solvent evaporation method is used in 
preparation of the microspheres21-22.  In brief, after production of the emulsion droplets 
via XME, DCM is extracted into the CP, where it is sparingly soluble.  The DCM is then 
readily evaporated from the collection vessel due to its low boiling point, yielding solid 
drug-loaded polymer microspheres. 
5.3.7 Sizing of Microspheres 
In most experiments, the droplets produced via XME are deformed from a sphere 
and into a prolate spheroid due to the shear stress imposed by the flowing CP.  This 
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complicates slightly the measurement of particle size.  The diameter of a droplet is 
measured in two ways.   In the simplified method, the major and minor diameters are 
measured manually from a video frame containing the droplet image.  When higher 
resolution and/or larger sample sizes are needed, an automated image analysis routine 
processes the images such that an ellipse can be fit to the droplet perimeter.  In both 
cases, the reported diameter is then calculated as the average of the major and minor 
diameters.  While an assumption that the particle takes the shape of a prolate spheroid 
with equivalent spherical diameter D = (Dminor2Dmajor)1/3 may be more appropriate for 
highly deformed particles, for the small deformations seen here the result is 
indistinguishable from this and other advanced diameter calculation techniques. 
5.3.8 Physical Properties 
Fluid physical properties are calculated in the following ways.  Densities are 
calculated by weighing a known volume of fluid.  Viscosity is measured by capillary 
viscometry in an Ubbelohde viscometer.  Interfacial tension is measured via the drop 
weight method, which was analyzed in detail by Yildirim, Xu and Basaran23.  In this 
technique, the interfacial tension between the two phases is inferred by measurement of 
the weight of a drop that falls from a needle tip, and applying an empirical correlation.  
By varying the rate of droplet production, we are able to measure the interfacial tension at 
the moment of drop snap-off, as a function of the drop period.  This dynamic interfacial 
tension is a complex phenomenon, and has been well described in a recent review paper 
by Eastoe and Dalton24.  The physical properties of the various DPs are provided in Table 
5.2. 
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Table 5.2 – Physical properties of decanol and polymer-loaded systems. 
 T=18°C DP Properties CP Properties CP/DP Calculated 
System 
ρ 
(kg/m3) 
μ 
(mPa-s)
ρ 
(kg/m3)
μ 
(mPa-s)
γ 
(mN/m) OhCP OhDP λ 
Decanol 824 13.6 998 0.98 9.5 0.034 0.514 13.9 
Polymer 1327 14.9 998 1.41 8.0* 0.053* 0.483* 10.6 
*evaluated at a drop period of Δt = 1s using the drop weight method23 
5.3.9 Calculation and Measurement of Channel Shear Rate 
To relate the measured CP volumetric flow rate QCP to the shear rate dv/dz in the 
center of the channel and at the membrane surface, we utilize an empirical expression 
proposed by Purday25 
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where H is the channel height, W is the channel width, and m is an empirical factor 
defined by m = 1.54W/H when H/W < 2/3.  This expression is far less cumbersome than 
the full analytical solution for laminar flow in a rectangular channel, and has minimal 
error across the range of conditions studied here. 
To confirm the predictions of Eq. (5.4), titania coated glass microspheres 
(Isospheres-T, Microsphere Technology, Edinburgh, UK) are used to observe the CP 
flow dynamics in situ.  The microspheres are observable as a dark spot on a bright 
background, but only when they are within the focal plane of the microscope.  Because 
we are interested in the velocity at the center of the channel, and the channel is wide with 
respect to its height, variations in the depth of observed microspheres are unimportant.  
By analyzing the movement of individual microspheres across adjacent video frames, the 
velocity of the microspheres and thus the carrier fluid can be calculated. 
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5.4 Results and Discussion 
We are primarily concerned with the size of the particles that are produced, and 
the rate of their production, and these factors can be controlled by two parameters within 
a given experiment: QCP and QDP. These flow rates are directly proportional to the more 
intuitive parameters of shear rate, dv/dz, and DP velocity, vDP = 4QDP/πD02.  Looking first 
at the size of droplets produced as a function of the shear rate, we find there is great 
similarity when comparing the PLG and decanol systems, see Figure 5.4.  This is 
surprising given the complexity of the PLG system relative to the decanol system.  Both 
show the expected trend of rapidly decreasing particle size with the initial increase in 
shear rate, followed by more gradual decreases as the shear rate is increased further.  This 
will be shown later to be consistent with the model presented in Eq. (5.1), which states 
that D ∝  (dv/dz)-1/2. 
 
Figure 5.4 – Drop diameter D as a function of CP shear rate dv/dz 
for the PLG (filled circles) and decanol (open circles) systems.  For 
both systems, D0 = 90µm, and the flow rates were similar at QDP = 
0.7mL/hr and QDP = 1.0mL/hr for the PLG and decanol systems, 
respectively. 
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In Figure 5.5, we examine the size of droplets produced as a function of QDP, 
while dv/dz is held constant.  In general, a small increase in D is expected as QDP is 
increased, as has been seen in both XME26-27 and in other geometries23.  Indeed, this trend 
is observed, and as can be seen, there is a significant difference in the functional 
relationship between the decanol and PLG systems.  The decanol system shows a gradual 
linear increase in D as QDP is increased, with a slope of about 20µm/(mL/hr).   The PLG 
system shows a similar increase in D at high flow rates, but shows a drastic change in D 
at low flow rates.  These two trends are consistently seen independent of the value of 
dv/dz.  It appears that the primary difference between the decanol and PLG systems is this 
dependence of particle size on production rate. 
 
Figure 5.5 – Drop diameter D as a function of DP flow rate QDP or 
velocity vDP for the PLG (filled circles) and decanol (open circles) 
systems.  For both systems, D0 = 90µm, and the CP shear rates were 
similar at dv/dz = 1210s-1 and dv/dz = 970s-1 for the PLG and decanol 
systems, respectively. 
Since in a production setting, the DP flow rate determines the rate of particle 
production, it is desirable to modify the size model given in Eq. (5.1) in such a way that 
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the model is predictive of particle size as a function of both dv/dz and QDP.  It is clear 
from Figure 5.5 that for decanol, at constant dv/dz, D = mQDP + b, where m and b are 
constants for a given shear rate.  In non-dimensional form, the relationship can be 
generalized to   
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where k1 is a constant for a given experiment with set dv/dz, and is expected to be a 
function of OhDP.  This relationship is consistent with what has been observed in the 
dripping faucet23, a geometry quite similar to that encountered in XME.  Of course this 
model is phenomenological in nature, and does little to help elucidate the cause of the 
phenomena we observe.  Yet it will prove useful in analyzing the differences seen 
between our simple decanol and complex polymer systems. 
While it seems natural when comparing these systems to utilize the dimensionless 
variables introduced earlier; such an approach is complicated by the complexities of the 
PLG system.  In particular, shear thinning of the CP, viscoelasticity of the DP, and 
dynamic interfacial tension can all cause the physical properties of the system to become 
functions of the process conditions, leading them to be coupled in non-trivial ways.  Thus 
before non-dimensionalizing the systems under study, we check the requisite physical 
properties for non-ideal behavior. 
PVA is a common polymeric surfactant for manufacturing PLG microspheres, 
due to its ability to lower interfacial tension and stabilize emulsion droplets against 
coalescence21-22.  Relative to pure water, it also raises the viscosity of the CP by about 
40% at a concentration of 1% by weight.  This then increases the shear stress at a given 
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shear rate.  But for polymer solutions, viscosity is often a function of shear rate, and 
typically decreases with increasing shear.  If this were the case, it would negate the 
assumed velocity profile and subsequent calculations.  Because of our ability to observe 
the region of droplet formation from the side, we use particle velocimetry to observe the 
velocity profile in situ25.  Typical results are provided in Figure 5.6.  For all cases studied, 
the experimentally measured vCP and dv/dz match the theoretical predictions from Eq. 
(5.4) to within experimental error, and thus we conclude that an assumption of constant 
viscosity in the CP is appropriate. 
 
Figure 5.6 – Distance from membrane surface as a function of 
continuous phase velocity vCP for the PLG system with a CP 
containing 1% PVA.  Solid points are experimentally measured 
velocities, the solid line is the theoretical prediction, and the dashed 
line is the slope at the wall based on a parabolic least-squares fit to the 
entire data set. 
Having examined the CP and finding no effects of the dissolved polymer, we now 
investigate the DP, where the polymer is present at much higher concentration and has 
higher molecular weight.  There are two possible effects that could influence the 
dynamics of our system.  As before, we would not be surprised to find that the viscosity 
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is shear thinning.  However, once the DP passes through the membrane and into the CP, 
it experiences only a moderate shear rate due to its high viscosity and stress continuity at 
the DP/CP interface.  In addition, DP shear viscosity only plays a minor role in the size 
model presented here, Eqs. (5.1) and (5.3).  Thus it is not expected that shear thinning in 
the DP will cause any deleterious behavior during XME.  It is also possible that elastic 
effects such as non-linear elongational viscosity could be observed, which result in long-
lived droplet necks, and thus droplets that detach far from the membrane pore along with 
numerous satellite drops16.  To test for this second possibility, we measure the diameter 
of a droplet neck, from the first instant of droplet formation up until the critical time of 
neck breakage, tc.  If no elastic effects are present, the neck diameter should decrease in 
size according to Dn ~ (tc - t)2/3.  Figure 5.7 shows the results, which are generated by 
imaging the process stroboscopically.  That is, by adjusting the dripping frequency to 
near a multiple of the frame rate we can access sub-millisecond dynamics with a 
conventional video camera.  In general, we see only slight differences between the 
decanol and PLG systems, and both systems display the expected scaling of Dn with t at 
times near the critical point.  Furthermore, we do not witness the long lived droplet necks 
seen elsewhere, thereby indicating the lack of significant elastic effects16, 28.   
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Figure 5.7 – Droplet neck diameter Dn as a function of time t for 
the PLG (filled circles) and decanol (open circles) systems. The 
difference in breakup time is due to slightly different production rates.  
The inset shows the same data plotted as Dn vs. (tc – t) on logarithmic 
coordinates, where tc is the critical time of neck breakage; the dashed 
line demonstrates the theoretically predicted slope of 2/3. 
Although not observed in the current system, in general, nonlinear elongational 
elasticity is expected to arise if the relaxation time of the polymer exceeds the 
characteristic flow time within the droplet neck, i.e. the Deborah number De = ελ &  > 1, 
where λ is the longest polymer relaxation time and ε&  is the highest strain rate of the flow 
field.  With the data collected in this study, we can calculate ε&  and λ as follows.  The 
strain rateε&  as the droplet nears snap off can be estimated28 as 
dt
dD
D
n
n
2
−=ε& , which 
results in 1s2400 −=ε&  for the data presented in Figure 5.7.   The relaxation time λ in 
dilute solutions can be estimated from Zimm theory29 
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where [η] is the intrinsic viscosity of the polymer solution, ηs is the solvent viscosity, Mw 
is the polymer molecular weight, R is the gas constant and T the temperature.  Even 
though the polymer concentrations used herein are far from dilute, we can use Eq. (5.6) to 
gain a rough idea of how close we are to the onset of elastic effects30.  Using ηs = μDP = 
14.9mPa-s, [η] = 57mL/g and Mw = 137 000g/mol, we calculate λ = 3 x 10-5s.  Thus De = 
0.07, significantly below the transition region.  Even though the solution viscosity is 
high, and this retards polymer relaxation, the molecular weight is low enough that the 
chains can fully recoil when strained, and hence elastic effects are not seen.  An analysis 
of the relationship  μDP = μDP(xPLG) (data not shown) reveals that a doubling of the DP 
polymer fraction, to xPLG = 18%, would result in De ≈ 1.  Similarly, a doubling of the 
polymer molecular weight to Mw = 270 000g/mol would also result in De ≈ 1.  For typical 
manufacturing of drug loaded polymer microspheres, these points represent extreme 
operating conditions, yet there are certainly other applications where high polymer 
concentration and/or  Mw could lead to elastic effects being observed. 
Moving now to an analysis of the effects of dynamics interfacial tension, in 
essence, we expect the interfacial tension at the moment of snap-off to differ significantly 
from its long-time value.  One conventional approach for characterizing the dynamic 
interfacial tension is the drop weight method23.  We performed such measurements, 
despite expecting the conditions during XME to differ somewhat from the dynamics of 
gravity driven drop break off from a needle tip.  To probe different time scales for droplet 
production, we use a variety of needle diameters and volumetric flow rates, all while 
maintaining the droplet production in the dripping regime.  The results are shown in 
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Figure 5.8.  As can be seen, the interfacial tension of the decanol system does not change 
significantly across the range of droplet frequencies studied, with a relative standard 
deviation of 6%.  But the PLG system shows a large effect, dropping from about γ = 
11mN/m at Δt = 0.5s to γ = 3mN/m at Δt = 30s.  For typical XME experiments conducted 
here, the time scale for droplet production Δt = πD3/6QDP ranges from Δt ≈ 0.01s to Δt ≈ 
1s.  Due to the dripping-jetting transition, we are unable to directly measure the 
interfacial tension at time scales less than Δt ≈ 0.5s, and thus we turn to modeling to 
predict what may occur at shorter times.  The phenomenological Rosen equation24 
predicts that at times infinitesimally close to zero, the interface will behave as if there is 
no surfactant adsorbed, and at very long times, surfactant will completely cover the 
interface, and the interfacial tension will plateau.  In between, a power law dependence is 
predicted: 
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where γ0 and γ∞ are the interfacial tensions at time zero and infinity, and τ and n are 
fitting constants.  We find γ0 by measuring the interfacial tension when no surfactant is 
present, and γ∞ by forming droplets over time periods greater than 500s.   Using these 
initial and terminal values, and then adjusting τ and n to fit the intermediate data, we find 
that the Rosen equation fits our drop weight method data well over the time period 
observed, with the average error being about 5%.   
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Figure 5.8 – Interfacial tension γ as a function of drop period Δt for 
the PLG (filled circles) and decanol (open circles) systems, as 
measured using the drop weight method23. The dotted line shows the 
average value of γ for the decanol system, and the solid line is a fit of 
the PLG data to Eq. (5.7). 
Summarizing the non-ideal effects investigated thus far, we have seen that shear 
thinning viscosity and fluid elasticity do not play a role in the dynamics of XME under 
the conditions studied here.  Interfacial tension, however, seems to change significantly 
over large time scales, and thus could be responsible for the differences seen in droplet 
size vs. production rate for the decanol and PLG systems.  Using the insight provided by 
the Rosen equation, we could directly substitute Eq. (5.7) into Eq. (5.5) to see if the 
results of Figure 5.5 can be predicted.  However, when γ is not constant, both Ca and We 
are affected simultaneously.  Thus it is more instructive to use Eq. (5.5) to directly 
compute γ using the measured flow rates and droplet diameters, as a function of the XME 
dripping period, shown in Figure 5.9. As expected, the results for the simple decanol 
system show no sign of dynamic interfacial tension, and yield an average value, 
9.63mN/m, consistent with what was measured via the drop weight method, 9.47mN/m. 
The scatter in the data is a consequence of the fact that γ  ~ D3, implied by Eq. (5.1), (5.2) 
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and (5.3), making the computed tension very sensitive to small errors in the measurement 
of droplet diameter. 
 
Figure 5.9 – Interfacial tension γ as a function of drop period Δt for 
the PLG (filled circles) and decanol (open circles) systems as 
calculated from Eq. (5.5) during XME. The dotted line shows the 
average value of γ for the decanol system, and the solid line is a fit of 
the PLG data to the Rosen equation. 
The PLG data do show the expected trend of decreasing interfacial tension with 
increasing droplet period, and the measured values are within the range observed 
previously, however the values are significantly lower than what is predicted by Eq. (5.7) 
at comparable dripping frequencies in both processes.  We again use the Rosen equation 
to fit the γ –Δt curve, and assume the same initial and terminal values γ0 and γ∞, with fit 
parameters shown in Table 5.3.  The time constant τ, which moves the curve horizontally, 
is an order of magnitude smaller for the XME data.  This is not surprising given that 
during XME, convection drives surfactant to the droplet interface, an effect not seen in 
the drop weight method.  Thus the droplet interface achieves a given surfactant 
concentration an order of magnitude faster during XME.  The exponent n, which changes 
the slope of the curve in log-log space, is about 1/3 of that measured via the drop weight 
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method.  A smaller slope is also predictable due to the strong convection present during 
XME.  When considering the strong convective forces, it could be considered surprising 
that interfacial tension changes at all as a function of drop period.  However, this result 
could be explained by a slow surfactant adsorption process.  Regardless, it seems that 
dynamic interfacial tension can be held solely responsible for the subtle non-ideal 
behavior we observe in the PLG system. 
Table 5.3 – Rosen equation fit parameters. 
Method γ0 (mN/m) γ∞ (mN/m) τ (s) n 
Drop weight 19.2 2.2 0.49 0.75 
XME 19.2 2.2 0.04 0.25 
 
Although dynamic interfacial tension provides an adequate explanation for the 
significant changes in D at low QDP seen in Figure 5.5, it is interesting to note that there 
is no significant dynamic interfacial tension effect observed in Figure 5.4, where D is 
plotted as a function of dv/dz.  Thus we are tempted to simplify the problem, and test the 
validity of Eq. (5.5) using a constant, average interfacial tension.  This simplification is 
further reinforced by the following fact.  We saw before that when calculating γ from 
measured values of D, errors are amplified because γ  ~ D 3.  However, when observing D 
in an environment with changing γ, the dynamics are dampened because D ~ γ 1/3.  Using 
this methodology, we construct Figure 5.10, assuming for the PLG system γ = 9.6mN/m, 
which is the average value in Figure 5.9 for drops produced across the same frequency 
range.  We find that the model does predict well the relationship between Ca and D/D0 
for both the decanol and PLG systems.  Yet we have argued that dynamic interfacial 
tension is present in the XME system.  We expect if dynamic interfacial tension is 
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present, as Ca is increased, smaller drops will be made at a higher frequency.  This 
shorter time period between drops means that the interfacial tension at the time of snap 
off will be higher, and thus the droplets will be slightly larger than otherwise expected.  
Thus, when dynamic interfacial tension is present in XME, instead of D/D0 ~ Ca-0.5, the 
exponent of Ca should be higher (closer to zero).  Testing this quantitatively, a power law 
fit to the PLG interfacial tension vs. time data presented in Figure 5.9 results in γ  ~ Δt -
0.11.  Using the fact that D ~ γ 1/3 and combining with Eq. (5.1), we find that the exponent 
of Ca should be -0.5+0.11/3 = -0.46.  Indeed, a power law fit to the PLG data presented 
in Figure 5.10 reveals D/D0 ~ Ca-0.46.  Consequently we conclude that an assumption of 
constant interfacial tension results in minimal error when calculating Ca and using Eq. 
(5.5), and the deviations from Eq. (5.5) can be readily determined if the relationship 
between γ  and Δt is known. 
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Figure 5.10 – Scaled diameter ratio (1/k)D/D0 as a function of 
capillary number Ca for the PLG (filled circles) and decanol (open 
circles) systems. The solid line is a prediction based on Eq. (5.5), 
(1/k)D/D0 = Ca-1/2. 
In the end, our goal is to understand the effects processing parameters have on the 
size of the particles produced, and the rate of their production, and use this information to 
manufacture monodisperse polymer particles.  Despite the sometimes non-ideal behavior 
that is seen when polymers and surfactants are introduced to the system, particles can be 
produced over a wide range of sizes and rates with a remarkable degree of precision.  An 
analysis using the automated sizing technique of n = 261 wet particles over a 10 min 
period reveals a relative standard deviation (RSD) of 1.2%, while an independent analysis 
of n = 81 close-packed, fully dry particles results in RSD = 1.6%.  See Figure 5.11 and 
Figure 5.12 for additional details.  This small variability demonstrates that the ability to 
manufacture uniform particles via XME is limited primarily by the operator's ability to 
control those parameters that appear in the size model, namely the flow rates QDP and 
QCP.   
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Figure 5.11 – Diameter histograms for wet and dry drug loaded 
PLG particles produced over a 10min time period, measured 
independently via image analysis.  The dry particles are shown in 
Figure 5.12.  The variables <D>, σ, and n refer to the mean, standard 
deviation, and number of samples, respectively.  We observe the ratio 
of dry and wet particle diameters to be Ddry/Dwet = 0.488, which is close 
to the expected value of Ddry/Dwet = (ρwet/ρdry xDP)1/3 = [(1)(0.122)]1/3 = 
0.496 because the dry particles have no porosity and the polymer has 
nearly identical density to the solvent. 
 
Figure 5.12 – Fully dry drug loaded PLG particles produced over a 
10min time period using the 60 μm membrane shown in Figure 
5.2(b), at a shear rate of dv/dz = 2150 ± 110 s-1.    In some locations 
two layers of particles can be seen.  The mean diameter is 124μm with 
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a standard deviation of 2 μm (n = 81).  A histogram of the sizes is 
shown in Figure 5.11. 
From an operational viewpoint, it is important to understand the influence the 
various model parameters have on the process.  First, the production rate per pore 
calculated on a mass basis, i.e. the mass flow rate, dm/dt, is simply the product of the DP 
solids fraction xDP with the total mass flow rate of the DP, dm/dt = xDPρDPQDP.  Increases 
in xDP make dm/dt rise proportionally, but make μDP, λ and OhDP increase much more 
quickly, decreasing process robustness.  In practice, solids loadings between 5% and 15% 
are common.  The flow rate QDP is the most logical parameter for raising dm/dt, but can 
not be increased indefinitely.  Changes to QDP modify We, the ratio of inertial forces to 
interfacial forces.  When We > 1, inertia dominates interfacial tension, and a jet is formed 
from the membrane pore.  Above this dripping-jetting transition, droplets break off far 
from the membrane pore and are typically polydisperse11.  Thus for normal operation, 
production is optimal when QDP is chosen such that We ≈ 1, which occurs for QDP = 
(γD03/ρDP)1/2.   At this condition, the production rate per pore is dm/dt = xDP(ρDPD03γ)1/2.  
For further increases in dm/dt, it makes sense to increase the number of pores until the 
desired production rate is achieved.  If each pore releases droplets into a common CP, 
care must be taken in spacing the pores so that the presence of one droplet does not 
interact with the growth and break off of nearby droplets.  Because a force-free droplet in 
a shear field only perturbs the flow field ~(D/r)-3, a single line of pores arranged 
diagonally relative to the flow would only need to be spaced by a few droplet diameters 
perpendicular to the flow to avoid perturbations from the single pore result.  A useful 
property of the XME system is that although variations in pore permeability might cause 
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QDP to vary from pore to pore, in the dripping regime this effect does not lead to a 
significant change in droplet diameter among pores. 
Using the size models and physical and geometric parameters, we can predict the 
range of particle sizes that are achievable using our XME system.  On the large end, 
particles can be manufactured up to the size restrictions set by the geometry of the 
system.  In order to make monodisperse spherical particles, care must be taken that 
gravitational forces do not exceed interfacial forces, i.e. the Bond number does not 
exceed unity, Bo = ρDPD2g/γ < 1.  For our system, this means that particles must remain 
below about 800µm in the wet state, or 400µm when fully dry.  On the small end, 
particles can be made as small as D/D0 ≈ 2, but only if high shear stresses are employed, 
which can be achieved through high μCP, high QCP, or small H.  Thus the minimum size 
of particles is set by D0, which we found to be at minimum D0 = 15µm for our 300µm 
thick membranes, resulting in 30µm wet or 15µm dry particles.  However, as reported by 
Yanagishita et al.31, advanced manufacturing techniques can be used to produce 
membranes and particles down to D ≈ D0 ≈ 100nm. 
When manufacturing particles via XME, care must be taken such that the particles 
remain uniform until they are ready to be used.  Unfortunately, natural processes such as 
coalescence and shear break up act to widen the particle size distribution.  In simple 
systems such as the decanol-water system studied here, droplets readily coalesce due to 
the absence of surfactant.  Addition of a surfactant does stabilize the particle size 
distribution from growing larger, but also decreases the interfacial tension, and thus 
weakens the droplets against shear breakup.  In the PLG system studied here, droplets are 
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stabilized by the surfactant PVA, and the interfacial tension continues to decrease over a 
droplet's lifetime as additional surfactant is adsorbed to the interface.  Our goal is to 
prevent shear breakup of the nascent PLG particles until such point that the solvent is 
extracted, thus generating solid particles with a stable size distribution. 
 
Figure 5.13 – Droplet deformation Df, (squares) and droplet size 
D/D0 (circles) as a function of Cadrop for the PLG system.  The 
deformation data utilize a linear fit, while the size data are fit according 
to Eq. (5.5). Rupture occurs at Df,c = 0.4.  The figure uses the same data 
set presented in Figure 5.10. 
Because shear is used to generate the initial monodisperse emulsions, the 
operating conditions during XME are inherently close to the critical condition where 
breakup of droplets occurs.  For insight into this potential problem, we look to the results 
of Bentley and Leal32 who used a four-roll mill to experimentally measure the 
deformation and point of breakup as a function of droplet capillary number, Cadrop, 
viscosity ratio, λ, and a flow parameter, α, which characterized the relative importance of 
elongation and shear in the flow field.  In their work, which primarily studied pure fluids, 
they utilized a deformation parameter Df to measure droplet deformation, where Df = (L-
B)/(L+B), and L and B are the lengths of the droplet's major and minor semiaxes, 
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respectively.  It was shown that for λ > 1, Df will increase linearly with Cadrop until it 
reaches Df,c ≈ 0.4, at which point the droplet will rupture.   
The critical value of  Cadrop where Df = 0.4 depends on λ and α, but typically 
varied from 0.1 < Cadrop < 0.5 for λ > 1.  Using the relationship between the different 
capillary numbers, Cadrop = 0.5CaD/D0, we plot Df and D/D0 against Cadrop using the same 
PLG data set that was previously presented.  Then we calculate the ratio of Ca needed to 
generate a droplet of a given size to the critical value where rupture is expected to occur, 
Cac.  Figure 5.13 and Figure 5.14 show these results. 
 
Figure 5.14 – Ratio of Ca to the critical value Cac where droplet 
rupture occurs, calculated as a function of the diameter ratio D/D0 
and viscosity ratio λ.  The solid line represents λ = 5, the dotted line is 
λ = 10, and the dashed line is λ = 20. 
We know already that XME can be used to generate emulsions down to D/D0 ≈ 2, 
but from these calculations we learn that the process is near an unstable operating point, 
where a small increase in shear rate downstream of the membrane pore could result in Ca 
> Cac.  As can be seen, increasing λ increases the stability of the system against shear 
breakup.  Fortunately, in a laminar flow, after a droplet is generated it will tend toward a 
position away from the wall29, where the shear rate is lower.  But care must be taken in 
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constructing the areas downstream of the membrane pore, as any bends or obstructions 
will increase the local shear rate, again increasing the likelihood of breakup.  This 
potential problem can be avoided through intelligent apparatus design, by expanding 
channel dimensions downstream of the pore, thus decreasing velocities and shear rates 
and thereby increasing the likelihood that the final size distribution will be uniform. 
5.5 Summary 
We have shown that XME is a robust technique that can be used for the 
production of complex polymeric particles as well as simple emulsion droplets.  The 
relationship between the size of droplets and the CP shear rate, derived elsewhere from 
first principles, was shown to apply equally well to the simple decanol-water system and 
a complex system containing a dissolved polymer, drug, and surfactant.  In contrast, the 
polymer system showed an unexpected scaling of droplet size as a function of the DP 
flow rate, which we have shown to be consistent with the presence of dynamic interfacial 
tension.  The inferred interfacial tension at a given dripping period was significantly 
lower than values measured independently at the same period using the drop weight 
method, which is not too surprising in light of the stagnant nature of the outer fluid in the 
latter method, slowing surfactant transport to the interface.  The CP velocity profile and 
the thinning dynamics of the DP droplet neck were both directly observed, and both were 
consistent with theoretical predictions for Newtonian fluids, indicating shear-thinning 
viscosity and fluid elasticity are negligible.  Detached droplets were seen to have an 
ellipsoidal deformation, which increased linearly with the capillary number.  Finally, the 
distribution of wet droplet sizes was consistent with measurements from close-packed 
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arrays of dry particles, and both result in a relative standard deviation of between 1 and 
2%.  In conclusion, over a wide range of conditions, the XME process can be used to 
manufacture monodisperse droplets of predictable size, even when the fluids contain 
dissolved polymers and surfactants.   
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Chapter 6: Future Work 
 
In the end, the desired outcome of this project was to demonstrate that cross-flow 
membrane emulsification (XME) can be used for the production of drug-loaded polymer 
microspheres with controllable release profiles that exceed the performance of existing 
commercial products.  While the original goal has not been met, the tools to accomplish 
this are in place such that a researcher need only follow the recipe presented in this 
chapter to make the proposed demonstration.  This chapter is organized as follows.  First, 
we lay out the requirements for designing long-acting release (LAR) formulations in 
general, and specifically a one month depot formulation of haloperidol, our model drug 
of choice.  Then we review existing literature on immediate and LAR haloperidol 
formulations.  This is followed by a review of the parameters that can be tuned in order to 
achieve the desired release duration and rate.  Finally, we end with what experiments 
would need to be run in order to complete the formulation design.  
6.1 Formulation Requirements 
The basic requirements for LAR formulations are that they are sterile, physically 
and chemically stable for at least two years when refrigerated, and stable for at least one 
week at room temperature.  Additionally, the product should be formulated so that no 
greater than 3 mL per injection site need be administered, and the product should be 
easily syringable (can be pushed through a syringe without requiring excessive force) 
through a 20 gauge 1.5 inch needle.  Additional requirements that would improve upon 
existing formulations are that an LAR product should not exhibit any burst release, and 
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should produce a near-constant release rate that is approximately equal to the average 
elimination rate for the drug. 
The model drug studied here, haloperidol, is especially well suited for controlled 
release applications.  The drug is indicated for use in the treatment of schizophrenia, as 
well as the control of tics associated with Tourette's Disorder.   It is well suited for 
controlled release applications1 due to the low daily dose, the drug hydrophobicity, high 
non-compliance rates in the intended treatement group, and existence of dose-
proportional side effects2.  Furthermore, the wealth of literature available on the drug aids 
in the formulation design.  Haloperidol is typically supplied as an oral dosage form, taken 
one or two times per day3.  For acute use, haloperidol injection USP is prescribed, and for 
chronic use, a LAR formulation of haloperidol decanoate is prescribed for monthly 
administration3.  In this case study, we will attempt to design a formulation that exceeds 
the performance of the existing haloperidol decanoate product.  
For a theoretical haloperidol LAR formulation, a review of existing data is helpful 
in the design.  An assortment of physical and chemical property data are provided in 
Chapter 3, and the reader is directed there for further information.  Table 6.1 displays 
pharmacokinetic data for intravenous and oral haloperidol, and intramuscular haloperidol 
decanoate. 
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Table 6.1 – Pharmacokinetic parameters for haloperidol.3-5 
Parameter Mean SEMa 
Elimination half life (hr) 26.2 8.0 
Volume of distribution (L/kg) 21.7 6.9 
Clearance (mL/kg/min) 10.8 2.6 
Elimination constant (1/hr) 0.030 - 
Bioavailability (relative AUC0-∞b)  0.65 0.14 
Plasma concentration for 10 mg oral dose (ng/mL) 7.79 4.79 
Plasma concentration for 100 mg decanoate dose (ng/mL) 7.95 4.94 
Plasma concentration before next dose (ng/mL) 2.62 0.27 
Dosing rate for 70 kg man (mg/day) 2.8 - 
 aSEM = standard error of the mean, bAUC0-∞ = area under the concentration – time curve 
A number of parameters from this table are relevant.  First, the drug has an incredibly 
large volume of distribution, indicating that it is absorbed in both the blood stream and 
tissues throughout the body.  The drug has a fairly high bioavailability, and thus the 
average daily dose administered via parenteral administration should not vary 
significantly from the daily oral dose.  Specifically, it has been found that patients 
receiving 10 mg/day oral haloperidol achieve the same steady state average blood serum 
concentration when 100 mg/month haloperidol decanoate injection is utilized.  We can 
also calculate the desired dosing rate (i.e. the amount of haloperidol released per day) by 
multiplying the clearance by the desired plasma concentration, yielding about 3 mg/day.  
Thus, this is the target quantity to be released from our PLG microspheres. 
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Figure 6.1 - Plot of average haloperidol blood serum concentration 
following a loading dose regimen of 100 mg haloperidol equivalent 
(administered as haloperidol decanoate).  The dosing schedule was 
once weekly for the first four weeks, then once every two weeks until 
week eight, and once every four weeks after week eight.5 
To achieve a release rate of 3 mg/day over the course of 30 days, then 90 mg must 
be administered.  A typical formulation might start with 20% drug loading (i.e. 1:4 drug 
to polymer ratio in the solvent).  If it is assumed that the encapsulation efficiency during 
the emulsification process is 100% then a 20% drug loading of the microspheres results.  
Thus, 450 mg of microspheres would be administered.  To suspend the microspheres, we 
assume that 100 mg microspheres per 1 mL of suspending medium would be used, and 
thus our injection volume would be 4.5 mL of medium plus about 0.5 mL for the 
microspheres, yielding 5 mL.  Thus two separate injections would be required, in order to 
stay under the 3 mL per injection site guideline.  This works out to be very similar to the 
marketed naltrexone LAR formulation, which has 112 mg microspheres per 1 mL of 
diluent, and is administered as two separate injections.6 
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6.2 Previous studies of haloperidol LAR formulations 
Many other researchers have published data on LAR formulations of haloperidol.  
Wang et al.7 used melt extrusion to generate haloperidol loaded rods at 40% drug loading 
in a matrix of 50:50 poly(DL-lactide-co-glycolide) (PLG) (inherent viscosity 0.47 dL/g), 
and compared this formulation to a 20% drug loaded solvent cast pellet.8  Although in 
vitro release experiments showed a roughly 7 day lag phase before significant drug was 
released from the rods, the same rods demonstrated in vivo in rats a serum concentration 
maximum on day 7, and continued release into the serum up until about day 40.  The 
study demonstrated that melt extrusion could be used to rapidly make implants that 
provide fairly consistent release over a prolonged period. 
Other studies investigating incorporation of haloperidol into PLG microspheres 
were conducted by Cheng et al.9 and by Budhian et al.10-11  Cheng et al. used high shear 
homogenization to generate particles, while Budhian et al. used ultrasonics, and both 
used a batch production system.  All found relatively constant release rates in vitro, and 
both studies demonstrated very low encapsulation efficiency and final drug loading, 
which is not surprising given that the particles produced were between 0.1 and 10 µm.  
Finally, Budhian et al. reported that the diffusivity of haloperidol in 50:50 PLG particles 
8 x 10-18 cm2/s, a finding that is useful for prediction of drug release rates from particles 
of different sizes. 
6.3 Future XME and in vitro release experiments 
The next step in the product design is the generation of microspheres that release 
at a rate of 3 mg/day at a drug loading of 20%.  Finding guidance from the work of other 
researchers, it appears that 50:50 PLG copolymers of intermediate inherent viscosity are 
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appropriate for developing once monthly LAR formulations of haloperidol.  Because 
PLG polymers break down by cleavage of the ester bond between lactide and/or 
glycolide residues, a higher inherent viscosity (which equates to higher initial molecular 
weight) results in a longer time period before the polymer completely breaks down and 
the microsphere disintegrates.  Thus polymer inherent viscosity is a key parameter that 
can be adjusted to affect drug release rate and duration, in addition to microsphere size.  
Based on this and other data reported thus far, a starting formulation for XME would look 
like that presented in Table 6.2. 
Table 6.2 – Starting compositions for once monthly haloperidol LAR formulation. 
Continuous Phase 
Component 
Composition 
(%) 
 Dispersed Phase 
Component 
Composition 
(%) 
poly(vinyl alcohol) 1  50:50 PLG  
(I.V. 0.47 dL/g) 
9.6 
haloperidol trace*  haloperidol 2.4 
water 99  dichloromethane 88 
 *concentration needed to achieve saturation 
At this point, the rate of drug release for a microsphere of a given size and 
composition would need to be determined.  The best way to accomplish this is to run a 
single XME experiment, and use the continuous phase (CP) flow rate to change 
microsphere size, while holding all other process variables constant.  It is recommended 
that about 4 different monodisperse size samples be collected, each containing at least 
200 mg of microspheres.  Because the CP is saturated with the drug, no mass transfer 
should occur during emulsification, and thus all samples should exhibit approximately 
100% encapsulation efficiency.  Using the procedures outlined in Chapter 3, the particles 
should be hardened, washed, filtered and dried.  
 121
Subsequent to the generation of the particles, the in vitro drug release can be 
measured using the existing apparatus described in Chapter 3.  Briefly, the dry 
microspheres are added to a dialysis chamber along with a small amount of release 
medium, and this chamber is sealed and placed in a larger reservoir of medium.  The 
release medium recommended is phosphate buffered saline at pH of 7.4 and a 
temperature of 37°C.  To better simulate the release environment in vivo, a surfactant 
such as polysorbate 80 should be added to the medium.  The surfactant improves 
microsphere wetting, and because of the very low solubility of haloperidol in water at pH 
= 7.4, it also acts to better simulate the sink conditions of the body.  In addition, an agent 
such as sodium azide should be employed in the release medium to control microbial 
growth.  The concentration of haloperidol in solution can be monitored using the inline 
UV spectrometer, and if the concentration exceeds approximately 10% of the equilibrium 
concentration (which is dependent on the surfactant), the release medium should be 
replaced.  Drug release should be monitored until no changes are observed for at least 
two weeks, at which point the dialysis chamber should be removed and inspected for 
particle residue.  If no residue is found, then the experiment is concluded, and the release 
rate, duration and total amount of drug released can be calculated. 
6.4 Achieving the optimal release profile 
Once a representative set of release experiments have been conducted, the 
protocol of Berchane et al. can be used to calculate what combination of monodisperse 
sizes should be combined to provide the closest match to the desired release profile.12  
This is possible because the release rate from a mixture of monodisperse sizes is simply 
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the weighted average of the individual release rates.  In brief, their protocol calls for the 
user to begin with a cumulative solution to the diffusion equation,  
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where Mt / M∞ is the ratio of mass released at time t to mass released at infinite time, R is 
the radius of the microsphere, and ∫= t dttDT 0 )( , where D(t) is the drug diffusivity at time 
t, which is a function of polymer molecular weight, and thus is a function of time.  The 
boundary and initial conditions used are c(r = R, t > 0) = 0 and c(r, t = 0) = ci, where c is 
concentration and r is radial position.  The diffusivity is linked to the polymer molecular 
weight through an empirical polynomial relationship, and molecular weight Mw decreases 
as a function of time, )exp()0( degtktMM ww −== , where kdeg is the degradation rate 
constant.  In the fitting, it is assumed that there exists an initial diffusivity, D0, which 
explains the burst release, and this diffusivity is used until the calculated diffusivity D(t) 
exceeds D0.  The parameters D0 and kdeg are the only parameters used to fit the release 
profile. This method has been demonstrated successfully in fitting release profiles for the 
drug piroxicam loaded into two different grades of PLG with three different microsphere 
diameters. 
Modeling provides great validation that drug release can be explained by a 
combination of diffusion and degradation, but ultimately we want to use the model to 
predict the combination of particle sizes that will result in the desired release rate.  
Berchane et al. were limited to three different size fractions, set by the standard sieve 
sizes used to separate their initially polydisperse size distributions.12  Still, they used a 
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non-linear least squares regression to minimize the squared error between the target 
release profile and a linear combination of the available profiles, and they achieved great 
success.  Using XME, a much wider range of release profiles is possible, because a much 
wider range of particle sizes is possible.  Instead of a discrete combination of 
monodisperse size distributions, the model can be used to create a smoothly varying 
function relating microsphere size and drug release rate from the initial release profiles.  
Modeling could then be used to generate a more detailed particle size population for use 
in constructing the ideal release profile, and a follow up XME experiment could be 
performed where the exact distribution is made within a single experiment.   
With the methods in this chapter as a guide, we conclude that generation of an 
ideal once-monthly formulation of haloperidol-loaded PLG microspheres using cross-
flow membrane emulsification is readily achievable.  And after this goal is achieved, the 
methods can be expanded to a much wider class of drugs and release profiles, with the 
potential result being a significant improvement in human health. 
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